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i 
Abstract 
Pharmaceuticals are a group of emerging organic compounds of environmental concern used extensively 
in human and veterinary medicine.  They are continually released into the environment as a result of 
manufacturing operations and excretion from humans and animals.  These compounds enter directly into 
the municipal sewage systems and into wastewater treatment plants.  A large number of important and 
potentially harmful organic contaminants, such as these pharmaceuticals, are not regulated in drinking 
and other waters.  As a result, conventional technologies at most waste water treatment plants (WWTPs) 
discharge water that meet regulatory standards, yet are not specifically designed to remove these organic 
contaminants.  Therefore, pharmaceutical compounds and their metabolites remain in discharged effluent 
and enter into the natural aquatic environment.  Concentrations of pharmaceutical residues measured in 
water are typically reported in the ranges of µg/L to ng/L, which are at least three to four orders of 
magnitude lower than that required to produce a pharmacological effect.  The probability of risks to 
humans arising from such an acute exposure is unlikely, but the possible effects resulting from life-long 
exposures and synergistic effects from exposure to many chemicals have yet to be determined.  It has 
been widely reported that pharmaceuticals and their metabolites that enter into the aquatic environment 
can have a potential harmful effect on the aquatic ecosystem and can reach drinking water sources.  This 
research focuses on non-steroid anti-inflammatory drugs (NSAIDs), a group of pharmaceuticals which are 
widely used as analgesic, antipyretic and anti-inflammatory agents. NSAIDs are frequently used because 
they are easily accessible as over the counter medication and are a group of drugs that do not produce 
addiction, respiratory depression, or drowsiness.  There is an incentive for removing NSAIDs and other 
pharmaceuticals from the aquatic environment.  Thus, quantitative evaluation of the fate of 
pharmaceuticals, proper risk assessment and improvement of the efficiency of WWTPs need sensitive and 
reliable analytical methods.  The purpose of this project was to provide a method for detecting three 
common NSAIDs, IBF, KTF, and NAP, in purified water with LLE-GC-FID. And, an investigation of 
UV photolysis, UV/H2O2, and UV/TiO2 AOPs was performed to determine their effectiveness in treating 
IBF, KTF, and NAP in purified water.  All treatment methods were successful in degrading target 
compounds with a total degradation of 86% or greater after 45 minutes.  A liquid-liquid extraction 
technique using methylene chloride and BSTFA + 1%TMCS derivatizing agent was determined for 
detecting low concentrations of IBF, KTF, and NAP with calibration curves showing good linearity with 
all R
2
 values greater than 0.9880. 
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Chapter 1:  Introduction 
Pharmaceuticals are a group of emerging organic compounds of environmental concern used extensively 
in human and veterinary medicine due to their continual release into the environment as a result of their 
manufacturing and excretion.  They are excreted primarily in urine and feces and also disposed of as 
unused or expired drugs mainly from household waste or pharmacies, whether directly into the domestic 
sewage system, septic systems, or landfills (Azzouz et al., 2010).  Steroid hormones are largely excreted 
by humans and animals, and they can enter the aquatic environment as parent compounds, active 
metabolites, conjugates, or a combination of both (Seifrtová et al., 2009).  These compounds enter 
directly into the municipal sewage systems and into wastewater treatment plants.  Extensive lists of 
important, and potentially harmful, classes of organic contaminants such as pharmaceuticals are not 
regulated in drinking and other waters.  As a result, conventional technologies at most waste water 
treatment plants (WWTPs) discharge water that meets regulatory standards, and are not specifically 
designed to remove these organic contaminants.  Therefore, pharmaceutical compounds or their 
metabolites remain in the discharged effluent and enter into the natural aquatic environment.  
Concentrations of pharmaceutical residues measured in water are typically reported in the ranges of µg/L 
to ng/L, which are at least three to four orders of magnitude lower than that required to produce a 
pharmacological effect.  The probability of risks to humans arising from such an acute exposure is 
unlikely, but the possible effects resulting from life-long exposures have yet to be determined (Kosjek et 
al., 2005).  It has been widely reported (Touraud et al., 2011; Parolini et al., 2009) that pharmaceuticals 
and their metabolites that enter into the aquatic environment can have a potential harmful effect on the 
aquatic ecosystem and can reach drinking water sources. 
 
Non-steroid anti-inflammatory drugs (NSAIDs) are a group of drugs widely used as analgesic, antipyretic 
and anti-inflammatory agents. NSAIDs are frequently used because they are a group of drugs that do not 
produce addiction, respiratory depression, or drowsiness (Pérez Pavón et al., 2009).  They are generally 
used without prescription with an estimated annual consumption of several hundred tons in developed 
countries (Ziylan et al., 2011).  NSAIDs are usually prescribed for treatment of acute or chronic 
conditions where pain or inflammation is present.  Due to their extensive use, NSAIDs have been one of 
the most commonly found pharmaceuticals in wastewater, river water, and drinking waters throughout the 
world (Farré et al., 2008). 
 
One of the most important classes of NSAIDs are the 2-aryl propionic acid derivatives, or profens.  Some 
of the most common compounds from this class are ibuprofen (IBF), ketoprofen (KTF), and naproxen 
(NAP). Figure 1 shows the basic structure of the three compounds: 
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Figure 1: Chemical Structures of Investigated Compounds: Ibuprofen (1), Naproxen (2), Ketoprofen (3) (Kosjek et al., 2005) 
IBF is widely used in treatment of rheumatic disorders, muscular pain, and fever and is a widely 
recognized drug with a huge global consumption.  It is excreted in a form of various conjugates with a 
high acute toxicity, and is suspected of endocrine disrupting activity in humans and wildlife.  KTF is an 
NSAID with analgesic and antipyretic effects and is classified as an acidic drug because of the presence 
of the carboxylic group in its chemical structure.  It is metabolized mainly in conjugation with glucuronic 
acid (carboxylic acid), and a large percent is excreted in urine.  NAP is widely used for mild to moderate 
pain relief and in treating osteoporosis, rheumatoid arthritis, menstruation and headaches.  Bioassay tests 
have shown that chronic toxicity of NAP is higher than its acute toxicity, and byproducts of 
photodegradation are more toxic then the parent compound (Ziylan et al., 2010). 
 
Taking completed research into consideration, it can be concluded that there is an incentive for removing 
IBF, KTF, and NAP, as well as other NSAIDs and steroid hormones, from the aquatic environment. Thus, 
quantitative evaluation of the fate of pharmaceuticals, proper risk assessment and improvement of the 
efficiency of WWTPs need sensitive and reliable analytical methods.  After an analytical procedure for 
determining NSAIDs is established, efficient treatment technologies capable of selectively and efficiently 
eliminating the parent compound as well as the active metabolites can be studied.  Research has shown 
that gas chromatography (GC) and liquid chromatography (LC) followed by flame ionization detection or 
mass chromatography (GC-FID, GC-MS, LC-MS) (Es’hagi, 2009, Azzouz et al., 2010, Sebok et al., 
2008) are viable analytical techniques for detecting low concentrations of pharmaceuticals in water. The 
most effective treatment methods have been advanced oxidation processes (AOPs) that include ozonation, 
sonification, ultraviolet (UV) photolysis, and UV/H2O2. 
1 
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Despite all of the research that has been done, more studies need to be conducted providing different 
analytical techniques and treatment methods for efficiently detecting and removing NSAIDs from water. 
Numerous papers show the detection of NSAIDS through LC-MS and GC-MS, but few have shown a 
simpler method with GC-FID. There are also few studies in the United States that have shown effective 
methods for treating NSAIDs in water. 
The purpose of this project was to provide a simple and fast method for detecting IBF, KTF, and NAP in 
purified waters by LLE-GC-FID.  LLE techniques were conducted utilizing methylene chloride as the 
solvent and BSTFA +1%TMCS as the derivatizing agent.  An investigation of UV photolysis, UV/H2O2, 
and UV/TiO2 AOPs was performed to determine their effectiveness of treating IBF, KTF, and NAP in 
purified water.  Concentrations of IBF, KTF, and NAP were determined using a UV-spectrophotometer.  
These objectives were accomplished by ascertaining US and international methods for detecting and 
treating IBF, KTF, and NAP in water and wastewater, researching the potential pathways for NSAIDs to 
enter the aquatic environment, the environmental risks and long term effects they pose to humans and the 
aquatic ecosystem, and the current treatment technologies that are being utilized. 
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Chapter 2: Background 
2.1 Non-Steroidal Anti-Inflammatory Drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of drugs used extensively as analgesic, 
antipyretic, and anti-inlammatory agents.  There wide use is due in part to several factors:  their non-
drowsy effect on the human body, they do not produce respiratory depression, and they are not addictive 
(Pérez Pavón et al., 2009). 
 
NSAIDs reduce pain and inflammation by blocking cyclo-oxygenases (COX), which are enzymes that are 
vital in producing prostaglandins.  NSAIDs can also cause internal bleeding because they block the COX-
1 enzyme, or the enzyme that protects the lining of the stomach from acid.  Complications from NSAIDs 
are estimated to cause approximately 6 deaths per 100,000 people in the United States, a death rate higher 
than that for cervical cancer and malignant melanoma (Peterson et al., 2010).  One of the most important 
classes of NSAIDs is the 2-aryl propionic acid derivatives, commonly known as profens.  This class 
includes the drugs ibuprofen, ketoprofen, and naproxen. 
 
IBF is commercially available as 2-(4-isobutylphenyl) propionic acid, and is extensively used for treating 
rheumatic disorders, muscular pain, and fever.  It is one of the most widely used NSAIDs in the world.  It 
is rapidly excreted in a number of conjugates, such as hydroxyl-IBF, carboxy, IBF, and carboxy-
hydratropic acid, the latter of which is known to have high toxicity and endocrine disrupting effects in 
humans and wildlife (Ziylan and Ince, 2011).  IBF has a molecular weight of 206.3 g mol
-1
, a solubility in 
water of 16 g L
-1
, a boiling point of 549.7°C at 760 mmHg, and a reported pKa between 4.53 and 5.2 
(Azzouz et al., 2010; Es’haghi, 2009).  Figure 2 shows the chemical structure for IBF. 
 
 
Figure 2:  Chemical Structure of IBF (http://chemistry.about.com/od/factsstructures/ig/Chemical-Structures---I/Ibuprofen-
Chemical-Structure.htm) 
KTF, or 2-(3-benzoyl-phenyl)-propionic acid is a non-steroidal anti-inflammatory drug with analgesic and 
antipyretic effects.  It is classified as an acidic drug because of the presence of the carboxylic acid in its 
chemical structure.  KTF is metabolized mainly in conjugation with glucuronic acid, and is excreted in 
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urine (Ziylan and Ince, 2011).  KTF has a molecular weight of 254.3 g mol
-1
, a solubility in water of 85 
mg L
-1
, a boiling point of 403.9°C at 760 mmHg, and a reported pKa between 4.33 and 4.45 (Azzouz et 
al., 2010; Es’haghi, 2009).  Figure 3 shows the chemical structure for KTF. 
 
 
Figure 3:  Chemical Structure of KTF (http://www.google.com/patents/EP2089007A2?cl=en) 
 
NAP, or (6-methoxy-α-methyl-2-napthalene acetic acid) is an NSAID widely used in mild to moderate 
pain relief and in treating osteoporosis, rheumatoid arthritis, and headaches.  NAP is also used in 
veterinary medicine in a number of ways.  Bioassay tests have shown that chronic toxicity of NAP is 
higher than its acute toxicity, and byproducts of photodegradation are more toxic than itself.  NAP has a 
molecular weight of 230.3 g mol
-1
, is nearly insoluble in water, a boiling point of 431.1°C at 760 mmHg, 
and a reported pKa between 4.15 and 4.50 (Azzouz et al., 2010; Es’haghi, 2009).  Figure 4 shows the 
chemical structure of NAP. 
 
 
Figure 4:  Chemical Structure of NAP (http://www.newdruginfo.com/pharmacopeia/usp28/v28230/usp28nf23s0_m55760.htm) 
 
2.2 NSAIDs in the Environment 
NSAIDs are widely used without prescription with an estimated consumption of several hundred tons in 
developed countries (Ziylan and Ince, 2011).  Consumed NSAIDs and their metabolites enter into the 
water systems primarily through excretion in feces or urine.  World-wide investigations on contamination 
levels by anti-inflammatory drugs such as IBF, KTF, and NAP have reported that individual 
 
6 
concentrations are within µg L
-1
 ranges in aquatic and surface water bodies, which suggests the higher 
concentrations in municipal sewage effluents (Mompelat et al., 2008; Maeng et al., 2010, Ziylan and Ince, 
2011).  Current treatment processes at WWTPs are not targeted to remove pharmaceuticals, including 
NSAIDs, thus many NSAID drugs and their metabolites are ultimately discharged into receiving water 
bodies.  The presence of these pharmaceuticals in the environment raises questions about the risk to 
human health and to the environment. 
 
2.2.1 Occurrence and Fate 
In developed countries, estimated consumption of NSAIDs is in the range of several hundred tons.  Table 
1 shows the relative consumption of IBF, KTF, and NAP in several European countries in recent past. 
 
Table 1:  Relative Consumption of IBF, KTF, and NAP in Developed European Countries (Zilyan and Ince. 2011) 
Compound Consumption (tons/year) Country 
IBF 
162 England (2000) 
25 Switzerland (2004) 
70 Finland (2002) 
345 Germany (2001) 
14.2 Australia (1998) 
KTF 
1.4 Finland (2002) 
0.25 Switzerland (2002) 
NAP 
35 England (2000) 
6.7 Finland (2002) 
22.8 Australia (1998) 
 
Based on this table and literature review, NSAIDs are essentially represented by IBF and several other 
compounds because they are the most extensively used and easily accessible.  Concentrations of NSAIDs 
are typically detected in µg L
-1
 ranges in aquatic and surface water bodies.  Lower concentrations have 
generally been detected in surface water then in WWTPs due dilution and potential elimination by natural 
pathways such as hydrolysis, sorption, biodegradation, and photolysis.  Many studies have shown that a 
variety of manufactured and naturally occurring organic compounds like NSAIDs have been detected in 
the proximity of municipal wastewater discharges and livestock agriculture facilities.  Pharmaceuticals 
have also been detected in untreated drinking water sources in the United States. 
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Focazio et al. (2008) conducted a national reconnaissance for pharmaceuticals and other organic waste 
contaminants in the United States for untreated drinking water resources.  The list contained 100 targeted 
chemicals and 63 were detected in at least one water sample.  Ibuprofen was detected in 74 samples and 
was part of a group that was the most frequently detected in surface waters.   
 
Mompelat et al. (2009) examined the characteristics, occurrence, and fate of numerous pharmaceuticals in 
drinking waters.  NSAIDs have higher recorded concentrations in surface waters with concentrations 
ranging between 0.4 ng L
-1
, and 15 µg L
-1
, with IBF being one of the most commonly found.   
 
The fate of pharmaceutical compounds leaving WWTP effluents or entering surface waters from 
agricultural runoff is first attenuated by dilution in surface waters to trace levels.  Other potential reducing 
forces in receiving waters is the adsorption on suspended solids, colloids, and natural dissolved organic 
matter (Mompelat et al., 2008).  Pharmaceutical compounds can also undergo biotic, chemical and 
phyisco-chemical transformations in water, even though they are manufactured to resist microbial 
degradation and remain chemically stable.  Pharmaceutical compounds undergo transformation mainly in 
surface waters with predominately direct and indirect photodegradation. 
 
2.2.2 Human and Environmental Health Risk 
With the increasing presence of pharmaceutical compounds in the environment, questions have arisen 
regarding the effects to humans and the aquatic environment.  Little information is available regarding 
human exposure to NSAIDs in the environment.  It is unknown if low level, long term exposure to 
NSAIDs in drinking waters pose a significant risk to human health.  However, it has been well established 
in literature that pharmaceuticals have had effects on the aquatic environment. 
 
Touraud et al. (2011) reviews the potential risk that NSAIDs can pose to human health.  Adverse 
ecological effects are attributed to endocrine disruptors, but no firm evidence of risk to human health has 
been determined.  Currently, quantitative pharmaceutical risk assessment studies have shown no 
appreciable human health risks associated with exposure of pharmaceuticals in water.  Risks and 
uncertainties still exist though for sensitive populations such as children, pregnant women and fetus, and 
allergic people.  Freshwater systems are exposed to thousands of compounds on a daily basis, with a large 
quantity including pharmaceuticals.  Toxicity of mixtures containing trace concentration levels of various 
pharmaceuticals is a beginning field and mixture effects are proving difficult to assess. Touraud explains 
that the key uncertainties are to identify which pharmaceuticals are of concern and what species are the 
most sensitive.  To date, the majority of studies regarding occurrence and impact on the environmental 
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health of pharmaceutical residues focused on drugs that are in high quantities, such as NSAIDs.  Touraud 
concludes that the scientific community needs to continue to research the possible effects that mixtures 
can have on human health risk and strategize ways to enhance public awareness of the impact of 
pharmaceuticals in the environment. 
 
Parolini et al. (2009) assessed a first screening evaluation of the cytogenotoxicity of IBF, diclofenac, and 
paracetamol using an in vitro biomarker approach on the haemocytes of the freshwater bivalve zebra 
mussel.  Genotoxicity was evaluated by single cell gel electrophoresis and DNA diffusion assay while 
cytotoxicity was evaluated by neutral red retention assay.  The exposure of the haemocytes to increasing 
concentrations of the three drugs, chosen based on the results of a viability test, revealed high 
cytogenotoxic potential and allowed the creation of the first toxicity scale for zebra mussel haemocytes.  
Ibuprofen was reported to be the most toxic of the three studies drugs.  The results laid the groundwork 
for in vivo exposures, which allow for better definition of observed cytogenotoxicity of the three 
compounds in a setting simulating real environmental exposure. 
 
2.3 Advanced Oxidation Processes (AOPs) 
Advanced oxidation processes rely on the generation of radicals, such as hydroxyl radicals, which are 
very reactive with many organic and inorganic compounds.  These radicals are very efficient in degrading 
the contaminant of concern and the by-products that are produced during the degradation process.  The 
general process for AOPs generally happens in the following order: 
 
1. Hydroxyl radicals react with organic compounds either by hydrogen removal, double bond 
addition, or electron transfer, ultimately leading to the formation of organic radicals 
2. The organic radicals react with dissolved oxygen to form peroxyl radicals or peroxide racials 
which undergo rapid decomposition 
3. The goal of the overall process results in the partial or total mineralization of organic 
pollutants 
 
Radicals can be generated through many different methods including ultraviolet photolysis, the 
combination of UV irradiation and hydrogen peroxide (H2O2), and heterogeneous photocatalysis 
(UV/TiO2). 
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2.3.1 UV Photolysis 
In photochemistry, chemical reactions proceed by the absorption of photons.  Electronic, vibrational and 
rotational energy states of the molecule can be excited by the energy of the photon.  An excited molecule 
can relax through various ways, such as ionization (fluorescence) and light emission (phosphorescence).  
The Jablonski diagram illustrates the electronic states of a molecule and the transitions between each 
state.  Figure 5 shows a version of the Jablonski diagram. 
 
 
Figure 5: Jablonski Diagram (http://www.olympusmicro.com/primer/java/jablonski/jabintro/index.html) 
 
The energy gained by a molecule when it absorbs a photon causes an electron to be promoted to a higher 
energy level.  Figure 5 depicts the main photophysical radiative and non-radiative processes for organic 
molecules in solution.  In this figure, So is the ground electronic state, S1 the first excited singlet state, S2 
is the second excited singlet state, and T1 is the first excited triplet state.  A second and third excited 
triplet state can exist as well.  Excited molecules lose their energy in non-radiative processes, when the 
molecule transfers its energy to the vibrating and rotating movements of the molecules in its environment. 
 
During the photolysis of water in a closed reactor, hydroxyl radicals and other oxidants are formed 
according to Reactions 1 through 3: 
 
 
10 
     Reaction 1 
 
     Reaction 2 
 
      Reaction 3 
 
Reaction 2 and Reaction 3 show the production of reactive hydroxyl radicals from the photolysis of H2O2 
and Reaction 3 shows the production of hydroperoxyl radicals, which are the protonated form of the 
superoxide, HO2.  Photolysis involves the interaction of artificial or natural light with the target molecule 
which induces photochemical reactions that lead to the degradation of the target molecule to intermediate 
and by-products.  Further degradation can result in mineralization end-products (Klavarioti et al., 2008). 
 
2.3.1.1 Literature Review 
Marotta et al. (2013) studied the kinetics of photodegradation of NAP under deaerated and aerated 
conditions.  The experiments were conducted under monochromatic irradiation (λ = 254nm) at pH = 7.0 
and T = 25°C.  Simplified reaction schemes for the photodegradation of NAP are proposed in the 
presence and in the absence of oxygen, respectively.  The schemes take into account the photolysis of 
NAP and its photoproducts as well as the reactions of the measured species with oxygen dissolved in the 
liquid bulk.  Two kinetic models were developed from the experimental results for both aerated and 
deaerated environments.  Calculated quantum yield of direct photolysis of naproxen under deaerated 
media was in good agreement with reported literature values.  The generation of singlet oxygen was 
analyzed for aerated conditions.  Overall, dissolved oxygen had a significant influence on the 
photodegradation rates of naproxen and the relative distribution of the major reaction intermediates. 
 
2.3.2 UV/H2O2 Photo-oxidation 
The effectiveness of direct photolysis increases with the addition of hydrogen peroxide (H2O2), a strong 
oxidant that dissociates into reactive hydroxyl radicals when irradiated with UV light.  The efficiency of 
UV/H2O2 degradation depends on the absorbance spectrum of the target compound, the quantum yield of 
photolysis, the concentration of H2O2, and the water matrix.  The water matrix, in particular, plays an 
important role in the efficiency of UV/H2O2 degradation.  Large quantities of organic matter in the water 
matrix can induce radical scavenging and decrease degradation (Klavarioti et al., 2008).  Reactions 4 
through Reactions 9 illustrate reactions that occur for UV/H2O2 degradation. 
 
        Reaction 4 
     Reaction 5 
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      Reaction 6 
       Reaction 7 
      Reaction 8 
    Reaction 9 
S 
2.3.2.2 Literature Review 
Benitez et al. (2010) studied the degradation of selected pharmaceuticals in water matrices by using 
several chemical treatments.  The pharmaceuticals studied were metoprolol, NAP, amoxicillin, and 
phenacetin.  The degradation of each analyte was conducted through UV radiation, ozone, Fenton’s 
reagent, photo-Fenton, UV radiation with ozone, UV radiation with H2O2, and TiO2.  The different water 
matrices studied were ultra-pure water, reservoir water, groundwater, and two secondary effluents from 
two municipal WWTPs.  The results showed that degradation rates increase by adding a second oxidant, 
and UV/TiO2 and O3/TiO2 systems provided the highest degradations rates overall.  It was also concluded 
that lower degradation rates were obtained with the pharmaceuticals dissolved in natural waters and 
secondary effluents due to the organic matter present in the water matrix which consume some amounts 
of the oxidant agents. 
 
Kim et al. (2009) studied the effectiveness of both UV and UV/H2O2 processes for the removal of 
pharmaceuticals in real wastewaters using a bench scale experiment with a treatment capacity of 10 m
3 
day
-1
.  Forty one pharmaceuticals, including KTF and NAP, were detected in secondary effluents.  UV 
processes showed 90% removal efficiency for KTF and 20 % removal efficiency for NAP.  UV/H2O2 
processes had a removal efficiency of over 90% for KTF and NAP.  Overall, UV/H2O2 processes showed 
the best removal efficiency compared to UV processes with a 90% removal efficiency in 39 
pharmaceuticals at a UV dose of 923 mJ/cm
2
.  The low UV dose indicates that it is possible to have a 
lower UV energy requirement for effective pharmaceutical removal by combination of UV/H2O2. 
 
2.3.3 UV/TiO2 Heterogeneous Photo-catalysis 
Heterogeneous photocatalysis using the semiconductor TiO2 is an emerging technology with advantages 
including ease of operation at ambient conditions, a cost effective method, and TiO2 is commercially 
available in various crystalline forms and particle characteristics.  Figure 6 shows the mechanism for TiO2 
photocatalytic degradation. 
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Figure 6:  Photocatalytic Degradation Mechanism (Murakami and Fujishima, 2010) 
 
The illumination of an aqueous TiO2 suspension with irradiation at a greater energy then the band gap 
energy (3.2 eV) generates valence bond holes and conduction band electrons.  Valence band holes can 
react with water and the hydroxide ion to generate hydroxyl radicals, while electrons react with adsorbed 
molecular oxygen reducing oxygen to superoxide radical anion (Klavarioti et al., 2008).  The superoxide 
radical anions can react with protons to form peroxide radicals.  Dissolved O2 concentration plays an 
important role on photocatalytic processes because they act as electron scavengers.  Valence band holes 
and electrons can undesirably recombine and hydroxyl radicals will not be produced if the dissolved 
oxygen concentrations decrease.  Therefore, transfer of hydroxyl radical to the solution limits the 
photocatalytic reaction. 
 
2.3.3.1 Literature Review 
Méndez-Arriaga et al. (2007) evaluated and compared the degradation of diclofenac, NAP, and IBF by 
heterogeneous TiO2 photocatalysis in aqueous solution at a laboratory scale.  Photocatalytic experiments 
were carried out in a Xe-lamp reactor in order to study different operational conditions such as catalyst 
load, temperature, and dissolved oxygen concentration.  The results showed that the optimum amount of 
TiO2, to achieve maximum degradation, of IBF was 1 g/L and 0.1 g/L for diclofenac and NAP.  
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Temperature only had an effect for NAP degradation, achieving almost 99% degradation.  No significant 
differences were observed for diclofenac or NAP at 20, 30, and 40°C.  The degradation of NAP and IBF 
was dependent on the dissolved oxygen concentration, but the rate of mineralization did not increase.  
Intermediate metabolites were detected in all cases.  Hydroxyl metabolites were the most important 
residual compounds after the photocatalytic treatment of IBF. 
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Chapter 3:  Methodology 
The essential goal of this thesis was to determine if UV, UV/H2O2, and UV/TiO2 treatment methods were 
effective at degrading IBF, KTF, and NAP in water.  Additionally, a simple and fast procedure for 
detecting low concentrations of IBF, KTF, and NAP in water was determined using LLE-GC-FID.  
Although this method may not detect very low concentrations of IBF, KTF, and NAP in water (i.e. ng L
-
1
), it does remove some of the burden that is associated with more tedious extraction techniques such as 
SPE and SPME.  Calibration curves with good linearity were established for UV spectrophotometer and 
gas chromatography.  UV, UV/H2O2, and UV/TiO2 treatment methods were conducted to degrade IBF, 
KTF, and NAP in water.  Conclusions were drawn from all experiments and future research pathways 
were recommended. 
 
3.1 UV-Spectrophotometer Sample Preparation and Measurement 
A 10 mg L
-1
 stock solution of IBF, NAP, and KTF (all received from Sigma – Aldrich) was prepared in 
purified water (Barnstead RO Nano Pure) and used for each experimental treatment.  Predetermined 
masses of IBF, KTF, and NAP were weighed using a Mettler Toledo (AB104-S) scale and added to 
purified water.  Stock solutions were stirred overnight and prepared weekly.  Standard solutions were 
prepared by diluting the stock solution with purified water to achieve the desired concentration.  The 
standard solution was adjusted to either pH 3 ±0.5 or pH 7.5 ± 0.5 by drop-wise addition of HCL or 
NaOH and measured with an Accument Basic AB 15 pH meter (Fisher Scientific). 
 
Optimal wavelengths for analysis of IBF, KTF, and NAP were identified by using the full scan function 
on a Varian - Cary 50 Scan UV-Visible Spectrophotometer.  A sample was placed in a quartz cuvette 
(10mm, rectangular, stoppered) and greatest absorbance peak was measured over a 500 nm to 190 nm 
spectrum in dual beam mode.  Appendix B contains the full scan curves for IBF, KTF, and NAP for 
standard curve development and contaminant concentration analyses.  The spectrophotometer was 
operated at a wavelength of 195 nm for IBF, 260 nm for KTF, and 230 nm for NAP.  Analysis of IBF, 
KTF, and NAP samples was completed before and after each treatment to determine the amount of IBF, 
KTF, and NAP removed. 
 
3.1.1 Standard Curves and Detection Limit Analysis 
In order to determine the unknown concentration of treated samples, standard concentration curves for 
below pKa and above pKa conditions for IBF, KTF, and NAP were constructed with samples of solutions 
at known concentrations.  Solutions ranging from 10 mg L
-1
 to the limit of detection (LOD) of IBF, KTF, 
and NAP were analyzed using the Varian – Cary 50 Scan UV-Visible Spectrophotometer to measure the 
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absorbance.  The correlation between the known concentration of the sample and the measured 
absorbance was used to develop the standard curves at both low and high pH conditions.  In addition, 
samples of a known concentration of IBF, KTF, and NAP were compared to blank samples using a T-test 
in Excel to determine the detection limit below which there was no longer a statistical difference between 
the blank sample and the one containing IBF, KTF, or NAP.  The t-test analyses are shown in Appendix 
D.   
 
3.2 Ultraviolet Degradation 
Ultraviolet treatment was performed in a laboratory scale batch reactor as shown in Figure 7.  The reactor 
was a glass tube apparatus and held a small UV lamp surrounded by 10 mL of sample. A Pen-Ray 5.5 
watt Lamp (ACE No. 12132-08), which is a low pressure mercury vapor lamp producing UV light at 254 
nm was used for all treatment experiments.  All experiments were conducted to a maximum exposure 
time of 45 minutes.  Additionally, experiments were performed at smaller time exposures to examine the 
effect the treatment method had on IBF, KTF, and NAP over the 45 minute time exposures.  The time 
trials were conducted with solutions of an initial concentration of 10 mg L
-1
 IBF, KTF, and NAP in 
purified water at below pKa and above pKa conditions. 
 
Figure 7:  UV Reactor with UV Light Apparatus 
 
 
 
 
 
 
UV Lamp 
Sample 
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3.3 Ultraviolet Degradation Time Trials 
Time trials were conducted for IBF, KTF, and NAP to determine the rate of reaction and overall 
degradation over a 45 minute period.   Treatment was performed at varying UV light exposure times up to 
a maximum of 45 minutes at both below pKa and above pKa conditions.  After the time trial was 
complete, the pH of each sample was recorded, and readjusted to its original condition if necessary.  The 
sample was analyzed by the spectrophotometer to determine the concentration. 
 
3.4 Ultraviolet Radiation with the Addition of Hydrogen Peroxide 
Degradation of IBF, KTF, and NAP was undertaken with ultraviolet radiation combined with hydrogen 
peroxide.  UV/H2O2 experiments were conducted by adding hydrogen peroxide to the solution before 
performing the same procedure described above for UV degradation.  Hydrogen peroxide was added to 10 
mg/L IBF, KTF, and NAP samples based on the most effective molar ratio.  Solutions were made of 
100:1, 50:1, and 10:1 molar ratios of hydrogen peroxide to IBF, KTF, and NAP.  The most effective 
molar ratio was determined by conducting an experiment for each molar ratio of hydrogen peroxide to 
IBF, KTF, and NAP for 30 minutes.  After 30 minutes, each sample was analyzed in the 
spectrophotometer for final absorbance and converted to final concentration.  Table 2 provides the most 
effective hydrogen peroxide molar ratios for IBF, KTF, and NAP.  Treatment was performed at varying 
UV light exposure times up to a maximum of 45 minutes at both below pKa and above pKa conditions.  
After the time trial was complete, the pH of each sample was analyzed, recorded, and readjusted to its 
original condition if necessary. 
 
3.5 Ultraviolet Radiation with the Addition of Titanium Dioxide 
Degradation of IBF, KTF, and NAP was undertaken with ultraviolet radiation combined with titanium 
dioxide (Titanium (IV) Oxide Powder, anatase, melting point of 1825
°
C, density of 3.9 mg L
-1
, Supelco 
Product # 232033).  UV/TiO2 experiments were conducted by adding titanium dioxide to the solution 
before performing the same procedure described above for UV degradation.  Titanium dioxide was added 
to 10 mg/L IBF, KTF, and NAP samples based on the most effective titanium dioxide dose.  Solutions 
were made of adding 200 mg L
-1
, 100 mg L
-1
, and 50 mg L
-1
 doses of titanium dioxide to IBF, KTF, and 
NAP.  The most effective dose was determined by conducting an experiment for each dose of titanium 
dioxide to IBF, KTF, and NAP for 30 minutes.  After 30 minutes, the sample was transferred into a glass 
centrifuge tube.  Each sample was centrifuged for 10 minutes at 3000 rpm to separate the treated sample 
from the powdered titanium dioxide.  Following centrifugation, the sample was analyzed in the 
spectrophotometer for final absorbance and converted to concentration.  Table 3 provides the most 
effective titanium dioxide dose for IBF, KTF, and NAP.  Treatment was performed at varying UV light 
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exposure times up to a maximum of 45 minutes at both below pKa and above pKa conditions.  After the 
time trial was complete, the pH of each sample was analyzed, recorded, and readjusted to its original 
condition if necessary. 
 
3.6 LLE-GC-FID Sample Preparation and Measurement 
A 1000 mg L
-1
 stock solution of IBF, KTF, or NAP was prepared in methanol graded for analytical 
purposes (Fisher Scientific).  Stock solutions were stored in capped amber glass jars and in the dark at 
4°C.  New stock solutions were prepared every 30 days.  Standard solutions were prepared by diluting the 
stock solution with purified water to achieve the desired concentration.  The standard solution was 
adjusted to pH 3.5 with 1N HCl and mixed with a magnetic stir bar.  Depending on the concentration of 
IBF, KTF, or NAP analyzed, either 800 mL or 1600 mL of sample was added to a 1 L or 2 L glass 
separatory funnel, respectively.  Methylene chloride (Fisher Scientific) was added in either 50 mL or 100 
mL aliquouts to the funnel and agitated, by shaking, for 2 minutes.  The separatory funnel cap was 
removed several times throughout the agitation process to release pressure build up inside the funnel.  
After agitation, the funnel was stabilized and the methylene chloride was allowed to separate from the 
water for 10 minutes.  Approximately 50 mL or 100 mL of methylene chloride was drained from the 
funnel into a glass evaporator tube.  The process was repeated a second time and the methylene chloride 
solutions were combined.  After methylene chloride collection, the sample aliquot was evaporated 
(RapidVap Labconco Evaporator) under a stream of nitrogen to near dryness and reconstituted in 1.5 mL 
of methylene chloride.  The 1.5 mL aliquot was collected in a GC vial and 100 µL or 200 µL of 
derivatizing agent, BSTFA + 1% TMCS (Supelco), was added to the sample.  The sample was placed in a 
laboratory oven (Lindberg/Blue) at 70 °C for 24 hours to allow the reaction to take place.  The vial was 
shaken intermittently throughout the 24 hour time period to ensure thorough mixing for the reaction.  
After derivatization was complete, the 1 µL of sample was injected into the GC-FID (Agilent 6890 
Series) for analysis.  Appendix I provides the evaporator and GC-FID settings used for all LLE-GC-FID 
experiments.  
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Chapter 4:  Results and Discussion 
The objective of this study was to obtain data for the degradation of IBF, KTF, and NAP from water 
using UV, UV/H2O2, and UV/TiO2 treatment methods.  A procedure for detecting low concentrations of 
the target compound using LLE-GC-FID was also determined.  The data was analyzed to determine if all 
treatment methods were effecting at degrading the target compounds. 
 
4.1 UV Spectrophotometer Calibration Curves 
Calibration curves were established for KTF and NAP for below pKa conditions and IBF, KTF, and NAP 
for above pKa conditions.  A calibration curve could not be established for IBF for below pKa conditions 
because a maximum absorbance peak could not be determined during the full scan analysis over IBF’s 
UV spectrum (Appendix B).  IBF was tested with the UV spectrophotometer at a wavelength of 195 nm, 
KTF at 260 nm, and NAP at 230 nm).  Below pKa and above pKa calibration curves for IBF, KTF, and 
NAP are plotted below in Figure 8 and Figure 9. 
 
 
Figure 8:  Below pKa Calibration Curves (λ = 260 nm (KTF); 230 nm (NAP)) 
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Figure 9:  Above pKa Combined Calibration Curves (λ = 195 nm (IBF); 260 nm (KTF); 230 nm (NAP)) 
 
All curves were considered accurate for quantification below concentrations of 10 mg/L, with R
2 
values 
above 0.9750. There is little difference in slope for NAP and KTF below pKa and above pKa conditions.  
The small difference in slope is surprising because the chemical structures of IBF, KTF, and NAP are 
different under below pKa and above pKa conditions.  All three compounds have a similar carboxylic 
acid groups attached to their structures.  At above pKa conditions, the carboxylic acid group is 
deprotonated from IBF, KTF, and NAP.  As such, it would be expected that the slopes would vary, which 
they do, but not to the extent anticipated. 
 
4.2 UV Photolysis Kinetics Experiments 
The rate law expresses the relationship of the rate of a reaction to the rate constant and the concentrations 
of the reactants raised to some power.  For a general reaction: 
 
the rate law takes the form 
 
where x and y exponents are numbers determined experimentally.  The x and y exponents specify the 
relationships between the concentrations of the reactants A and B and the reaction rate.  Added together, 
they give the overall reaction order, or the sum of the powers to which all reactant concentrations 
appearing in the rate law are raised. 
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In a first order rate law in a batch reaction, 
 
    Equation 1 
 
where 
[A] = concentration of NSAID 
t = time (min) 
k = rate constant (min
-1
) 
 
The integrated form of Equation 1 is 
 
   Equation 2 
 
Equation 2 has the form of a linear equation.  As is expected during the course of a reaction, the 
concentration of A decreases with time.  The model for a first order reaction is a plot of  versus 
time, which gives a straight line with a slope equal to –k and a y intercept equal to . 
 
In a second order rate law in a batch reactor, 
 
   Equation 3 
 
The integrated form of Equation 3 is 
 
   Equation 4 
 
Equation 4 has the form of a linear equation.  The model for a second order reaction is a plot of   
versus t and gives a straight line with a slope equal to k and y intercept equal to . 
 
It is common to simplify second order reactions to pseudo first order rate equations.  If the above general 
reaction is carried out under the conditions where the concentration of one of the reactants is in excess to 
the other, then the concentration of the excess reactant will not change significantly over the course of the 
entire reaction.  The pseudo first order rate law has the appearance of a first-order reaction. 
 
 
21 
4.2.1 Ibuprofen UV Photolysis Kinetics 
UV photolysis kinetics time trials were conducted for IBF at above pKa conditions with an initial 
concentration of 10 mg L
-1
 for a total time of 45 minutes.  Figure 10 shows the IBF degradation data for 
the above pKa conditions and demonstrates that 45 minutes was an adequate time to achieve steady state 
conditions. 
 
 
Figure 10:  IBF UV Degradation Kinetics Above pKa (λ = 254 nm, 5.5 W) 
 
The rate was determined to be second order by graphing the inverse of the final concentration after each 
time trial versus irradiation time, which resulted in a straight line with a slope of –k.  Figure 11 contains 
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Figure 11:  IBF Above pKa 2nd Order Kinetics (λ = 254 nm, 5.5 W) 
 
4.2.2 Ketoprofen UV Photolysis Kinetics 
UV photolysis kinetics time trials were conducted for KTF at below and above pKa conditions with an 
initial concentration of 10 mg L
-1
 for a total time of 45 minutes.  Figure 12 shows the KTF kinetics data 
for the below and above pKa conditions and demonstrates that 45 minutes was an adequate time to 
achieve steady state conditions. 
 
 
Figure 12:  KTF UV Degradation (λ = 254 nm, 5.5 W) 
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The rate was determined to be first order by graphing the natural log of the final concentration after each 
time trial versus irradiation time, which resulted in a straight line with a slope of –k.  Figure 13 contains 
the first order plots for KTF UV below pKa and above pKa conditions.  The rate law constants for KTF 
below pKa and above pKa conditions were found to be 0.113 min
-1
 (R
2
 = 0.9868) and 0.0737 min
-1
 (R
2
 = 
0.9371). 
 
 
Figure 13:  KTF 1st Order UV Kinetics (λ = 254 nm, 5.5 W) 
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UV photolysis kinetics time trials were conducted for KTF at below and above pKa conditions with a 
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 for a total time of 45 minutes.  Figure 14 shows the KTF 
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time to achieve steady state conditions. 
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Figure 14:  NAP UV Degradation (λ = 254 nm, 5.5 W) 
 
The rate was determined to be first order by graphing the natural log of the final concentration after each 
time trial versus irradiation time, which resulted in a straight line with a slope of –k.  Figure 15 contains 
the first order plots for NAP UV below pKa and above pKa conditions.  The rate law constants for NAP 
below pKa and above pKa conditions were found to be 0.103 min
-1
 (R
2
 = 0.8950) and 0.119 min
-1
 (R
2
 = 
0.9472). 
 
Figure 15:  NAP UV 1st Order Kinetics Combined (λ = 254 nm, 5.5 W) 
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4.2.4 UV Photolysis Kinetics Summary 
UV photolysis treatment readily degraded IBF, KTF, and NAP for below pKa and above pKa conditions 
and the kinetic order of each photodegradation reaction was found to fit a first or second order kinetics 
model.  KTF and NAP showed the greatest degradation for both below pKa and above pKa conditions. 
 
Marotta et al. (2013) studied the photodegradation of naproxen under monochromatic irradiation at pH 7 
and 25°C under both deaerated and aerated conditions.  Under aerated conditions, the results showed that 
NAP is almost completely degraded in 2 hours.  This work showed that NAP is almost completely 
degraded in 45 minutes under limited aerated conditions with similar temperatures and pH values. 
 
4.3 UV/H2O2 Oxidation Kinetics 
The degradation of IBF, KTF, and NAP was evaluated for three different molar ratios of H2O2:NSAID for 
both below pKa and above pKa conditions for 30 minutes.  Molar ratios for IBF, KTF, and NAP under 
each condition were selected based on the overall degradation after 30 minutes. Molar ratios were 
selected based on literature review and beginning concentrations of IBF, KTF, and NAP.  Table 2 
provides the molar ratio data for the degradation of IBF, KTF, and NAP under below pKa and above pKa 
conditions. 
 
Table 2:  H2O2:Contaminant Molar Ratios for IBF, KTF, and NAP. 
NSAID Condition Molar Ratio (mg L
-1
) Final Concentration adter 30 min(mg L
-1
) 
IBF Above pKa 
10:1 0.853 
50:1 0.964 
100:1 1.105 
KTF 
Below pKa 
10:1 0.587 
50:1 0.575 
100:1 0.242 
Above pKa 
10:1 0.808 
50:1 0.589 
100:1 0.270 
NAP 
Below pKa 
10:1 0.404 
50:1 0.105 
100:1 0.173 
Above pKa 
10:1 0.393 
50:1 0.224 
100:1 0.378 
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Based on the experimental data, a 10:1 molar ratio was used for IBF above pKa conditions, a 100:1 molar 
ratio was used for KTF below pKa and above pKa conditions, and a 50:1 molar ratio was used for NAP 
below pKa and above pKa conditions. 
 
4.3.1 Ibuprofen UV/H2O2 Oxidation Kinetics 
UV/H2O2 oxidation kinetics experiments were conducted for IBF at above pKa conditions with a initial 
concentration of 10 mg L
-1
 for a total time of 45 minutes.  Figure 16 shows the IBF kinetics data for the 
below and above pKa conditions and demonstrates that the concentration of IBF levels out to 
approximately 1 mg L
-1
 after 45 minutes of UV light exposure. 
 
 
Figure 16:  IBF UV/H2O2 Degradation Above pKa ((λ = 254 nm, 5.5 W, H2O2:IBF Molar Ratio – 10:1)) 
 
The rate was determined to be second order by graphing the inverse of concentration versus time, which 
resulted in a straight line with a slope of –k.  Figure 17 contains the second order plot for IBF UV/H2O2 
above pKa conditions.  The rate constant for above pKa conditions was found to be 0.028 min
-1
 (R
2
 = 
0.9161).   
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Figure 17:  IBF UV/H2O2 2nd Order Kinetics Above pKa (λ = 254 nm, 5.5 W, H2O2:IBF Molar Ratio – 10:1) 
 
4.3.2 Ketoprofen UV/H2O2 Oxidation Kinetics 
UV/H2O2 oxidation kinetics time trials were conducted for KTF at below pKa and above pKa conditions 
with a constant initial concentration of 10 mg L
-1
 for a total time of 45 minutes.  Figure 18 shows the KTF 
kinetics data for the below and above pKa conditions and demonstrates that the concentration of KTF for 
below pKa conditions and above pKa conditions after 45 minutes of UV light exposure is 0.257 mg L
-1
 
and 0.029 mg L
-1
, respectively. 
 
Figure 18:  KTF UV/H2O2 Degradation Combined (λ = 254 nm, 5.5 W, H2O2:KTF Molar Ratio – 100:1) 
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The rate was determined to be first order by graphing the natural log of the final concentration after each 
time trial versus irradiation time, which gives a straight line with a slope of –k.  Figure 19 contains the 
first order plots for KTF UV/H2O2 below pKa and above pKa conditions.  The rate law constants for 
below pKa and above pKa conditions were found to be 0.091 min
-1
 and 0.124 min
-1
.  Figure 19 shows that 
the rate of reactions for above pKa is greater than the rate for below pKa conditions. 
 
 
Figure 19:  KTF UV/H2O2 1st Order Kinetics (λ = 254 nm, 5.5 W, H2O2:KTF Molar Ratio – 100:1) 
 
4.3.3 Naproxen UV/H2O2 Oxidation Kinetics 
UV/H2O2 oxidation kinetics time trials were conducted for NAP at below pKa and above pKa conditions 
with a constant initial concentration of 10 mg L
-1
 for a total time of 45 minutes.  Figure 20 shows the 
NAP kinetics data for the below and above pKa conditions and demonstrates that the concentration of 
NAP for below pKa conditions and above pKa conditions after 45 minutes of UV/H2O2 oxidation is 0.107 
mg L
-1
 and 0.163 mg L
-1
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Figure 20:  NAP UV/H2O2 Degradation (λ = 254 nm, 5.5 W, H2O2:NAP Molar Ratio – 50:1)) 
 
The rate was determined to be first order by graphing the natural log of the final concentration after each 
time trial versus reaction time, which gives a straight line with a slope of –k.  Figure 21 contains the first 
order plots for KTF UV/H2O2 below pKa and above pKa conditions.  The rate law constants for below 
pKa and above pKa conditions were found to be 0.253 min
-1
 and 0.145 min
-1
.  Figure 21 shows that the 
rate of reactions for below pKa is greater than the rate for above pKa conditions, yet the overall 
degradation after 45 minutes are within approximately 0.05 mg L
-1
. 
 
 
Figure 21:  NAP 2nd Order UV/H2O2 Kinetics (λ = 254 nm, 5.5 W, H2O2:NAP Molar Ratio – 50:1) 
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4.3.4 Summary 
UV/H2O2 treatment readily degraded IBF, KTF, and NAP for both below pKa and above pKa conditions 
and the rate constant for each oxidation reaction was found through a first or second order kinetics model.  
NAP and KTF showed the greatest degradation for both below pKa and above pKa conditions compared 
to IBF and KTF UV/TiO2 treatment.  It is noted that the above pKa kinetics for NAP better fit the second 
order model than the first order model, and the below pKa kinetics first and second order models both fit 
adequately.  A first order model was chosen rather than a second order model because it has been 
hypothesized that UV/H2O2 kinetics follows a pseudo-first order model.  It is assumed that the hydroxyl 
radicals are the excess reactant, and thus the change in concentration is negligible and a first order model 
can be used. 
 
Mendez-Arriaga et al. (2010) evaluated H2O2:IBF ratios ranging from 0.001:1 to 10:1.  When the IBF 
solution was irradiated in the presence of H2O2, almost 40% degradation took place after 2 hours.  They 
also concluded that a greater degradation rate was observed with UV/H2O2 then just UV photolysis, which 
is not consistent with the results found in this paper.  UV photolysis treatment of IBF had a greater 
reaction rate and greater overall degradation then UV/H2O2 treatment. 
 
4.4 UV/TiO2 Oxidation Kinetics 
Several studies (Rizzo et al., 2008, Klavarioti et al., 2008; Konstantinou et al., 2003) have indicated that 
experimental results of TiO2 photocatalytic oxidation of organic contaminants fit the Langmuir-
Hinshelwood (L-H) kinetic model.  The L-H model shows 
 
 
 
Where r is the reaction rate, k
’
 is the reaction rate constant, C is the concentration of the reactant, K is the 
adsorption coefficient, and θ is the fractional site coverage for the reactant.  For dilute aqueous solutions 
(KC<<1), as is the case of pharmaceuticals which are detected in water at low concentrations, the L-H 
model simplifies to a pseudo-first-order kinetic equation. 
 
For the purpose of this analysis, the data for TiO2 photocatalytic oxidation of IBF, KTF, and NAP was fit 
to either a first-order or second-order model.  The data was intended to model IBF, KTF and NAP in 
WWTP effluents, which are assumed to exist at low concentrations in dilute aqueous solutions. 
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The degradation of IBF, KTF, and NAP was evaluated at three different TiO2 doses under both below 
pKa and above pKa conditions for 30 minutes.  TiO2 doses for IBF, KTF, and NAP under each condition 
were selected based on the overall degradation after 30 minutes. Doses were selected based on literature 
review and starting concentration of IBF, KTF, and NAP (Mendez-Arriaga et al., 2008; Rizzo et al., 
2009).  Table 3 provides the TiO2 dose data for the degradation of IBF, KTF, and NAP under below pKa 
and above pKa conditions. 
 
Table 3:  TiO2 Dose Analysis for IBF, KTF, and NAP 
NSAID Condition pHf Dose (mg L
-1
) Final Concentration after 30 min (mg L
-1
) 
IBF Above pKa 
5.72 50 1.202 
6.13 100 1.272 
6.50 200 1.106 
KTF 
Below pKa 
2.68 50 1.051 
2.68 100 1.002 
2.66 200 1.320 
Above pKa 
6.16 50 2.155 
5.84 100 1.5660 
5.74 200 2.3160 
NAP 
Below pKa 
2.74 50 0.3253 
2.62 100 0.4868 
2.79 200 0.3132 
Above pKa 
6.12 50 0.7268 
5.65 100 0.6031 
5.57 200 0.4957 
 
Based on the experimental data, a 200 mg L
-1
 TiO2 dose was used for IBF above pKa conditions, a 100 
mg L
-1
 TiO2 dose was used for KTF below pKa and above pKa conditions, and a 200 mg L
-1
 TiO2 dose 
was used for NAP below pKa and above pKa conditions. 
 
4.4.1 Ibuprofen UV/TiO2 Oxidation Kinetics 
UV/TiO2 photocatalytic oxidation kinetics experiments were conducted for IBF at above pKa conditions 
with a constant initial concentration of 10 mg L
-1
 for a total time of 45 minutes.  Figure 22 shows the IBF 
kinetics data for the below and above pKa conditions and demonstrates that the concentration of IBF 
levels out to approximately 1 mg L
-1
 after 45 minutes of UV light exposure. 
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Figure 22:  IBF UV/TiO2 Oxidation Above pKa (λ = 254 nm, 5.5 W, TiO2 Dose – 200 mg L
-1
) 
 
The rate was determined to be second order by graphing the inverse of concentration versus time, which 
resulted in a straight line with a slope of –k.  Figure 23 contains the second order plot for IBF UV/TiO2 
above pKa conditions.  The rate law constant for above pKa conditions was found to be 0.020 min
-1
 (R
2
 = 
0.9016).   
 
 
Figure 23:  IBF UV/TiO2 2nd Order Kinetics Above pKa (λ = 254 nm, 5.5 W, TiO2 Dose – 200 mg L
-1
) 
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4.4.2 Ketoprofen UV/TiO2 Oxidation Kinetics 
UV/TiO2 photocatalytic oxidation time trials were conducted for KTF at below pKa and above pKa 
conditions with a constant initial concentration of 10 mg L
-1
 for a total time of 45 minutes.  Figure 24 
shows the KTF kinetics data for the below and above pKa conditions and demonstrates that the 
concentration of KTF for below pKa conditions and above pKa conditions after 45 minutes of UV light 
exposure is 0.255 mg L
-1
 and 1.396 mg L
-1
, respectively. 
 
 
Figure 24:  KTF UV/TiO2 Oxidation (λ = 254 nm, 5.5 W, TiO2 Dose – 100 mg L
-1
) 
 
The rate was determined to be second order by graphing the inverse of concentration versus time, which 
gives a straight line with a slope of –k.  Figure 25 contains the second order plots for KTF UV/TiO2 
below pKa and above pKa conditions.  The rate law constants for below pKa and above pKa conditions 
were found to be 0.078 min
-1
 and 0.014 min
-1
.  Figure 25 shows that the rate of reaction is greater under 
below pKa conditions when compared to the rate of reaction of above pKa conditions. 
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Figure 25:  KTF 2nd Order UV/TiO2 Kinetics (λ = 254 nm, 5.5 W, TiO2 Dose – 100 mg L
-1
) 
 
4.4.3 Naproxen UV/TiO2 Oxidation Kinetics 
UV/TiO2 photocatalytic oxidation kinetics time trials were conducted for NAP at below pKa and above 
pKa conditions with a constant initial concentration of 10 mg L
-1
 for a total time of 45 minutes.  Figure 26 
shows the NAP kinetics data for the below and above pKa conditions and demonstrates that the 
concentration of NAP for below pKa and above pKa conditions after 45 minutes of UV light exposure is 
0.306 mg L
-1
 and 0.287 mg L
-1
, respectively. 
 
Figure 26:  NAP UV/TiO2 Oxidation (λ = 254 nm, 5.5 W, TiO2 Dose – 200 mg L
-1
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The rate was determined to be second order by graphing the inverse of concentration versus time, which 
resulted in a straight line with a slope of –k.  Figure 27 contains the second order plots for NAP UV/TiO2 
below and above pKa conditions.  The rate law constants for above and below pKa conditions were found 
to be 0.080 min
-1
 and 0.077 min
-1
, respectively.  Figure 27 shows that the rate of reactions was very 
similar for both below pKa and above pKa conditions. 
 
 
Figure 27:  NAP 2nd Order UV/TiO2 Oxidation (λ = 254 nm, 5.5 W, TiO2 Dose – 200 mg L
-1
) 
 
4.4.4 Summary 
UV/TiO2 treatment readily degraded IBF, KTF, and NAP under both below pKa and above pKa 
conditions and the kinetic order of each photodegradation reaction was found to follow a second order 
kinetics model.  NAP showed the greatest degradation for both below pKa and above pKa conditions 
compared to IBF and KTF UV/TiO2 treatment.  It is hypothesized that all UV/TiO2 experiments were best 
fit to second order models because of concentrations of hydroxyl radicals and superoxide anions.  
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with hydroxyl radicals located in the valence holes.  If dissolved oxygen concentrations are reduced to 
zero, conduction band electrons can recombine with valence hydroxyl radical and reduce the rate of 
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for IBF, KTF, and NAP after 20 minutes of treatment.  It is hypothesized that the dissolved oxygen levels 
were reduced and the rate slowed appreciably.  
 
Mendez-Arriaga et al. (2008) reported that UV/TiO2 oxidation of IBF and NAP was modeled with first-
order kinetics and achieved the highest degradation with TiO2 loads of 1000 mg L
-1
 and 100 mg L
-1
, 
respectively.  A strong influence by photolysis was observed in the case of NAP, which is consistent with 
the results found in this report.  Mendez Arriaga et al. measured the free oxygen consumption of 
dissolved oxygen in the report.  It was concluded that the reaction rate was significantly dependent on the 
oxygen concentration because of its electron scavenging in the conduction band.  If the oxygen levels 
were insufficient, a high recombination of e
-
/h
+
 pairs is reached and hydroxyl radicals are no longer 
produced and available to react.  Oxygen levels were not measured in this report, but may have had an 
effect on the reactions and should be considered for future research. 
 
4.5 Gas Chromatography Calibration Curves 
Calibration curves were established for IBF, KTF, and NAP using LLE-GC-FID using the procedure 
described in the methodology chapter.  All compounds showed good linearity with R
2
 values greater than 
0.9880.  Figures 28 to 30 show the calibration curves for IBF, KTF and NAP.  IBF showed the best 
linearity with concentrations ranging from 0.01 mg L
-1
 to 50 mg L
-1
.  Naproxen was not soluble in water 
at 50 mg L
-1
, therefore a calibration curve was only established for a maximum concentration of 10 mg L
-
1
. 
 
Figure 28:  IBF LLE-GC-FID Calibration Curve (Elution Time: ~ 30.5 min) 
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Figure 29:  KTF LLE-GC-FID Calibration Curve (Elution Time:  ~52.1 min) 
 
 
 
Figure 30:  NAP LLE-GC-FID Calibration Curve (Elution Time:  ~46.6 min) 
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Chapter 5:  Conclusions and Recommendations 
UV, UV/H2O2, and UV/TiO2 treatments are potentially successful methods for removing IBF, KTF, and 
NAP from water.  Total degradation was 86% or greater after 45 minutes for all treatment methods 
analyzed.  Ibuprofen data was best fit to a second-order model for UV, UV/H2O2, and UV/TiO2 data.  
KTF and NAP were best fit to either first-order or second-order models.  All TiO2 experiments were best 
fit to second-order models.  In regards to these treatment methods applicability to industry, pilot scale 
experiments should be conducted for all treatments methods with different types of water and a wide 
variety of parameters (pH levels, temperature, organic matter levels, H2O2 molar ratios, TiO2 loads, etc.).  
The purpose of the experiments in this report were to conclude that these treatment methods have the 
ability to degrade IBF, KTF, and NAP in purified water, but it is unknown how efficient UV, UV/H2O2, 
and UV/TiO2 treatments are at degrading target compounds in real waters.  Additionally, other treatment 
methods should be investigated for their efficiency of target compounds as well. 
 
Calibration curves were established for IBF, KTF, and NAP using LLE-GC-FID with good linearity and 
R
2
 values greater than 0.9880.  The liquid-liquid extraction procedure performed for all GC experiments 
is a simple method that can detect IBF, KTF, and NAP at low concentrations (μg L-1).  Further 
optimization such as volume of solvent, volume of derivatizing agent, and GC parameters is required to 
detect lower levels of IBF, KTF, and NAP.  Solid phase extraction (SPE) and solid phase micro-
extraction (SPME), and more selective procedures should also be investigated and conducted to extract 
low concentrations of IBF, KTF, and NAP (ng L
-1
). 
 
Several recommendations for future research can be drawn from the results found in this paper.  By-
products and intermediates of IBF, KTF, and NAP should be investigated.  Degradation models for IBF, 
KTF, and NAP for concentrations expected in the environment (ng L
-1
 to μg L-1) should be performed in 
purified water to understand the behavior patterns of target compound degradation.  Detection of mixtures 
of pharmaceuticals and their effects to UV, UV/H2O2, and UV/TiO2 treatments should be investigated as 
well.  Furthermore, detection of pharmaceuticals in real water applications and oxidation experiments 
should be performed to study the effects of the treatments on real waters.  Additional experiments should 
include effects of pharmaceuticals on aquatic life and if low level, long term exposure of pharmaceuticals 
is a risk to human health. 
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Appendix A – Glossary of Terms 
 
AOP:  Advanced Oxidation Process 
COX:  Cyclo-oxygenases 
GC-MS:  Gas Chromatography-Mass Spectrometer 
H2O2:  Hydrogen Peroxide 
IBF:  Ibuprofen 
KTF:  Ketoprofen 
LC-MS:  Liquid Chromatography – Mass Spectrometer 
LLE-GC-FID: Liquid-Liquid Extraction – Gas Chromatography – Flame Ionization Detector 
NAP:  Naproxen 
NSAID:  Non-Steroidal Anti-Inflammatory Drug 
O3:  Ozone 
TiO2:  Titanium Dioxide 
UV:  Ultraviolet 
WWTP:  Waste Water Treatment Plant 
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Appendix B – UV-vis Spectrophotometer Spectrum for Investigated Compounds 
 
Ibuprofen 
 
 
Figure 31:  IBF UV-vis Spectrophotometer Spectrum Below pKa 
 
 
 
Figure 32:  IBF UV-vis Spectrophotomer Spectrum Above pKa 
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Figure 33:  KTF UV-vis Spectrophotometer Spectrum Below pKa 
 
 
 
Figure 34:  KTF UV-vis Spectrophotometer Spectrum Above pKa 
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Figure 35:  NAP UV-vis Spectrophotometer Spectrum Below pKa 
 
 
 
Figure 36:  NAP UV-vis Spectrophotometer Spectrum Above pKa 
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Appendix C – Calibration Curve and Limit of Detection Raw Data 
 
Ibuprofen Calibration Curve Data 
 
Table 4: IBF Calibration Curve Data:  Below pKa 
Concentration 
[C] 
Absorbance 
Range 
Corrected Absorbance 
Mean Absorbance 
Standard 
Deviation 
95% 
Confidence 
pH 
D1 D2 D3 D1 D2 D3 
0 0.4297 0.4242 0.4361 0.0119 -0.0003 -0.0058 0.0061 0.0000 0.0049 0.0121 2.59 
0.005 0.4191 0.4373 0.4224 0.0182 -0.0109 0.0073 -0.0076 -0.0037 0.0079 0.0197 2.63 
0.01 0.4853 0.4879 0.4884 0.0031 0.0553 0.0579 0.0584 0.0572 0.0014 0.0034 2.62 
0.05 0.4351 0.4321 0.4485 0.0164 0.0051 0.0021 0.0185 0.0086 0.0071 0.0177 2.60 
0.1 0.4747 0.4676 0.4619 0.0128 0.0447 0.0376 0.0319 0.0381 0.0052 0.0130 2.67 
0.5 0.4699 0.4695 0.4788 0.0093 0.0399 0.0395 0.0488 0.0427 0.0043 0.0107 2.66 
1 0.5323 0.5158 0.5174 0.0165 0.1023 0.0858 0.0874 0.0918 0.0074 0.0185 2.65 
2.5 0.9524 0.9433 0.9587 0.0154 0.5224 0.5133 0.5287 0.5215 0.0063 0.0157 2.64 
5 1.3087 1.2935 1.3139 0.0204 0.8787 0.8635 0.8839 0.8754 0.0087 0.0215 2.65 
7.5 1.7976 1.7731 1.7812 0.0245 1.3676 1.3431 1.3512 1.3540 0.0102 0.0253 2.60 
10 2.1067 2.1156 2.0984 0.0172 1.6767 1.6856 1.6684 1.6769 0.0070 0.0174 2.77 
 
Table 5:  IBF Calibration Curve Data:  Above pKa 
Concentration 
[C] 
Absorbance 
Range 
Corrected Absorbance 
Mean Absorbance 
Standard 
Deviation 
95% 
Confidence 
pH 
D1 D2 D3 D1 D2 D3 
0 0.0003 0.0001 0.0003 -0.0002 0.0001 -0.0001 0.0001 0.0000 0.0001 0.0002 8.25 
0.001 -0.0011 0.0000 0.0002 -0.0002 -0.0013 -0.0002 0.0000 -0.0005 0.0006 0.0014 6.85 
0.005 0.0083 0.0069 0.0087 0.0018 0.0081 0.0067 0.0085 0.0077 0.0008 0.0019 6.67 
0.01 0.0249 0.0257 0.0268 0.0019 0.0247 0.0255 0.0266 0.0256 0.0008 0.0019 7.51 
0.05 0.0604 0.0587 0.0584 0.0020 0.0602 0.0585 0.0582 0.0589 0.0009 0.0022 7.10 
0.5 0.1094 0.1074 0.1068 0.0026 0.1092 0.1072 0.1066 0.1076 0.0011 0.0028 6.48 
1 0.2030 0.2041 0.2036 0.0011 0.2028 0.2039 0.2034 0.2033 0.0004 0.0011 7.26 
2.5 0.4934 0.4918 0.4928 0.0016 0.4932 0.4916 0.4926 0.4924 0.0007 0.0016 6.41 
5 1.0891 1.0539 1.0677 0.0352 1.0889 1.0537 1.0675 1.0700 0.0145 0.0360 8.79 
7.5 1.4631 1.4742 1.4607 0.0135 1.4629 1.4740 1.4605 1.4658 0.0059 0.0146 6.65 
10 1.9419 1.9431 1.9643 0.0224 1.9417 1.9429 1.9641 1.9495 0.0103 0.0256 7.39 
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Ketoprofen Calibration Curve Data 
 
Table 6:  KTF Calibration Curve Data:  Below pKa 
Concentration 
[C] 
Absorbance 
Range 
Corrected Absorbance 
Mean Absorbance 
Standard 
Deviation 
95% 
Confidence 
pH 
D1 D2 D3 D1 D2 D3 
0 0.0003 0.0001 0.0003 0.0002 0.0001 -0.0001 0.0001 0.0000 0.0001 0.0002 2.59 
0.05 0.0008 0.0005 0.0002 0.0006 0.0006 0.0003 0.0000 0.0003 0.0002 0.0006 2.59 
0.1 0.0066 0.0037 0.0063 0.0029 0.0064 0.0035 0.0061 0.0053 0.0013 0.0032 2.67 
0.25 0.0129 0.0128 0.0128 0.0001 0.0127 0.0126 0.0126 0.0126 0.0000 0.0001 2.58 
0.5 0.0319 0.0324 0.0322 0.0005 0.0317 0.0322 0.0320 0.0319 0.0002 0.0005 2.66 
1 0.0630 0.0622 0.0626 0.0008 0.0628 0.0620 0.0624 0.0624 0.0003 0.0008 2.59 
2.5 0.1676 0.1677 0.1675 0.0002 0.1674 0.1675 0.1673 0.1674 0.0001 0.0002 2.57 
5 0.3171 0.3182 0.3197 0.0026 0.3169 0.3180 0.3195 0.3181 0.0011 0.0026 2.61 
7.5 0.4940 0.4934 0.4935 0.0006 0.4938 0.4932 0.4933 0.4934 0.0003 0.0007 2.59 
10 0.6349 0.6438 0.6343 0.0006 0.6347 0.6436 0.6341 0.6374 0.0043 0.0108 2.54 
 
 
Table 7:  KTF Calibration Curve Data:  Above pKa 
Concentration 
[C] 
Absorbance 
Range 
Corrected Absorbance 
Mean Absorbance 
Standard 
Deviation 
95% 
Confidence 
pH 
D1 D2 D3 D1 D2 D3 
0 0.0002 0.0000 0.0001 0.0001 0.0001 -0.0001 0.0000 0.0000 0.0001 0.0002 8.25 
0.005 -0.0006 -0.0008 -0.0009 0.0003 -0.0007 -0.0009 -0.0010 -0.0009 0.0001 0.0003 6.97 
0.01 0.0001 0.0001 0.0001 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 6.88 
0.05 0.0024 0.0024 0.0024 0.0000 0.0023 0.0023 0.0023 0.0023 0.0000 0.0000 6.67 
0.1 0.0097 0.0097 0.0096 0.0001 0.0096 0.0096 0.0095 0.0096 0.0000 0.0001 8.69 
0.5 0.0351 0.0357 0.0330 0.0021 0.0350 0.0356 0.0329 0.0345 0.0012 0.0029 6.40 
1 0.0683 0.0640 0.0669 0.0014 0.0682 0.0639 0.0668 0.0663 0.0018 0.0044 6.85 
2.5 0.1668 0.1669 0.1667 0.0001 0.1667 0.1668 0.1666 0.1667 0.0001 0.0002 8.57 
5 0.3202 0.3186 0.3219 -0.0017 0.3201 0.3185 0.3218 0.3201 0.0013 0.0033 7.05 
7.5 0.5111 0.5106 0.5110 0.0001 0.5110 0.5105 0.5109 0.5108 0.0002 0.0005 6.86 
10 0.6375 0.6390 0.6351 0.0024 0.6374 0.6389 0.6350 0.6371 0.0016 0.0040 8.75 
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Naproxen Calibration Curve Data 
 
Table 8:  NAP Calibration Curve Data:  Below pKa 
Concentration 
[C] 
Absorbance 
Range 
Corrected Absorbance 
Mean Absorbance 
Standard 
Deviation 
95% 
Confidence 
pH 
D1 D2 D3 D1 D2 D3 
0 0.0006 0.0002 0.0004 -0.0002 0.0002 -0.0002 0.0000 0.0000 0.0002 0.0004 2.59 
0.01 0.0008 0.0016 0.0010 0.0008 0.0004 0.0012 0.0006 0.0007 0.0003 0.0008 2.60 
0.05 0.0136 0.0143 0.0129 0.0014 0.0132 0.0139 0.0125 0.0132 0.0006 0.0014 2.60 
0.075 0.0217 0.0214 0.0216 0.0003 0.0213 0.0210 0.0212 0.0212 0.0001 0.0003 2.61 
0.1 0.0337 0.0309 0.0302 0.0035 0.0333 0.0305 0.0298 0.0312 0.0015 0.0038 2.64 
0.5 0.1622 0.1603 0.1630 0.0027 0.1618 0.1599 0.1626 0.1614 0.0011 0.0028 2.71 
1 0.3234 0.3221 0.3228 0.0007 0.3230 0.3217 0.3224 0.3224 0.0005 0.0013 2.68 
2.5 0.6892 0.6899 0.6881 0.0018 0.6888 0.6895 0.6877 0.6887 0.0007 0.0018 2.61 
5 1.5951 1.5905 1.5951 0.0046 1.5947 1.5901 1.5947 1.5932 0.0022 0.0054 2.60 
7.5 1.9733 1.9874 1.9826 0.0141 1.9729 1.9870 1.9822 1.9807 0.0059 0.0145 2.57 
10 2.6592 2.6837 2.6694 0.0245 2.6588 2.6833 2.6690 2.6704 0.0100 0.0250 2.61 
 
 
Table 9:  NAP Calibration Curve Data:  Above pKa 
Concentration 
[C] 
Absorbance 
Range 
Corrected Absorbance 
Mean Absorbance 
Standard 
Deviation 
95% 
Confidence 
pH 
D1 D2 D3 D1 D2 D3 
0 0.0006 0.0002 0.0004 0.0002 0.0002 -0.0002 0.0000 0.0000 0.0002 0.0004 8.25 
0.001 0.0005 0.0004 0.0003 0.0002 0.0001 0.0000 -0.0001 0.0000 0.0001 0.0002 6.99 
0.005 0.0013 0.0013 0.0013 0.0000 0.0009 0.0009 0.0009 0.0009 0.0000 0.0000 6.36 
0.01 0.0057 0.0063 0.0056 0.0007 0.0053 0.0059 0.0052 0.0055 0.0003 0.0008 6.54 
0.05 0.0168 0.0167 0.0170 0.0003 0.0164 0.0163 0.0166 0.0164 0.0001 0.0003 6.48 
0.1 0.0361 0.0390 0.0379 0.0029 0.0357 0.0386 0.0375 0.0373 0.0012 0.0030 6.85 
0.5 0.1903 0.1882 0.1921 0.0039 0.1899 0.1878 0.1917 0.1898 0.0016 0.0040 7.33 
1 0.3721 0.3728 0.3708 0.0020 0.3717 0.3724 0.3704 0.3715 0.0008 0.0021 8.85 
2.5 0.7952 0.7953 0.7953 0.0001 0.7948 0.7949 0.7949 0.7949 0.0000 0.0001 7.95 
5 1.8089 1.8072 1.8082 0.0017 1.8085 1.8068 1.8078 1.8077 0.0007 0.0017 8.70 
7.5 2.1917 2.1879 2.1927 0.0048 2.1913 2.1875 2.1923 2.1904 0.0021 0.0051 7.51 
10 2.7305 2.7363 2.7209 0.0154 2.7301 2.7359 2.7205 2.7288 0.0064 0.0158 6.56 
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Appendix D – Limit of Detection Analysis 
 
Ibuprofen:  Above pKa Limit of Detection Analysis 
 
t-Test: Two-Sample Assuming Equal 
Variances 
α 0.05 
 
      0 ppm 0.001 ppm 
 
Mean 0 
-
0.000533333 
 Variance 1.33333E-08 0.00000049 
 Observations 3 3 
 Pooled Variance 2.51667E-07 
  Hypothesized Mean Difference 0 
  df 4 
  t Stat 1.302061534 
  
P(T<=t) one-tail 0.13140585 
 
Accept Null Hypothesis because p > 0.05 
(Means are the same) 
t Critical one-tail 2.131846786 
  
P(T<=t) two-tail 0.2628117 
 
Accept Null Hypothesis because p > 0.05 
(Means are the same) 
t Critical two-tail 2.776445105   
  
 
 
   t-Test: Two-Sample Assuming 
Unequal Variances 
α 0.05 
 
      0 ppm 0.001 ppm 
 
Mean 0 
-
0.000533333 
 Variance 1.33333E-08 0.00000049 
 Observations 3 3 
 Hypothesized Mean Difference 0 
  df 2 
  t Stat 1.302061534 
  
P(T<=t) one-tail 0.161332995 
 
Accept Null Hypothesis because p > 0.05 
(Means are the same) 
t Critical one-tail 2.91998558 
  
P(T<=t) two-tail 0.322665989 
 
Accept Null Hypothesis because p > 0.05 
(Means are the same) 
t Critical two-tail 4.30265273   
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Ketoprofen:  Below pKa Limit of Detection 
 
t-Test: Two-Sample Assuming Equal 
Variances 
   
      0 ppm 0.05 ppm 
 Mean 0 0.000266667 
 Variance 1.33333E-08 0.00000009 
 Observations 3 3 
 Pooled Variance 5.16667E-08 
  Hypothesized Mean Difference 0 
  df 4 
  
t Stat 
-
1.436842416 
  
P(T<=t) one-tail 0.112061193 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical one-tail 2.131846786 
  
P(T<=t) two-tail 0.224122386 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical two-tail 2.776445105   
  
 
 
   t-Test: Two-Sample Assuming Unequal Variances 
  
      0 ppm 0.05 ppm 
 Mean 0 0.000266667 
 Variance 1.33333E-08 0.00000009 
 Observations 3 3 
 Hypothesized Mean Difference 0 
  df 3 
  
t Stat 
-
1.436842416 
  
P(T<=t) one-tail 0.123151565 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical one-tail 2.353363435 
  P(T<=t) two-tail 0.24630313 
 
Accept null hypothesis because p > 0.05 
t Critical two-tail 3.182446305   
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Ketoprofen:  Above pKa Limit of Detection 
 
t-Test: Two-Sample Assuming Equal 
Variances 
   
      0 ppm 0.01 ppm 
 
Mean 0 0 
 
Variance 0.00000001 0 
 Observations 3 3 
 Pooled Variance 0.000000005 
  Hypothesized Mean Difference 0 
  df 4 
  
t Stat 0 
  
P(T<=t) one-tail 0.5 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical one-tail 2.131846786 
  
P(T<=t) two-tail 1 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical two-tail 2.776445105   
  
 
 
   t-Test: Two-Sample Assuming 
Unequal Variances 
   
      0 ppm 0.01 ppm 
 Mean 0 0 
 Variance 0.00000001 0 
 Observations 3 3 
 Hypothesized Mean Difference 0 
  df 2 
  t Stat 0 
  
P(T<=t) one-tail 0.5 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical one-tail 2.91998558 
  
P(T<=t) two-tail 1 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical two-tail 4.30265273   
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Naproxen:  Below pKa Limit of Detection 
 
t-Test: Two-Sample Assuming Equal Variances 
  
      0 ppm 0.01 ppm 
 Mean 9.03502E-21 0.000366667 
 Variance 0.00000004 2.33333E-08 
 Observations 3 3 
 Pooled Variance 3.16667E-08 
  Hypothesized Mean Difference 0 
  df 4 
  t Stat -2.523573073 
  
P(T<=t) one-tail 0.032554253 
 
Reject null hypothesis because p < 0.05 
(Means are not the same) 
t Critical one-tail 2.131846786 
  
P(T<=t) two-tail 0.065108507 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical two-tail 2.776445105   
  
 
 
   t-Test: Two-Sample Assuming Unequal Variances 
  
      0 ppm 0.01 ppm 
 Mean 9.03502E-21 0.000366667 
 Variance 0.00000004 2.33333E-08 
 Observations 3 3 
 Hypothesized Mean Difference 0 
  df 4 
  t Stat -2.523573073 
  
P(T<=t) one-tail 0.032554253 
 
Reject null hypothesis because p < 0.05 
(Means are not the same) 
t Critical one-tail 2.131846786 
  
P(T<=t) two-tail 0.065108507 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical two-tail 2.776445105   
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Naproxen:  Above pKa Limit of Detection 
 
t-Test: Two-Sample Assuming Equal 
Variances 
   
      0 ppm 0.001 ppm 
 Mean 9.03502E-21 0 
 Variance 0.00000004 0.00000001 
 Observations 3 3 
 Pooled Variance 0.000000025 
  Hypothesized Mean Difference 0 
  df 4 
  t Stat 6.99849E-17 
  
P(T<=t) one-tail 0.5 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical one-tail 2.131846786 
  
P(T<=t) two-tail 1 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical two-tail 2.776445105   
  
 
 
   t-Test: Two-Sample Assuming Unequal Variances 
  
      0 ppm 0.001 ppm 
 Mean 9.03502E-21 0 
 Variance 0.00000004 0.00000001 
 Observations 3 3 
 Hypothesized Mean Difference 0 
  df 3 
  t Stat 6.99849E-17 
  
P(T<=t) one-tail 0.5 
 
Accept null hypothesis because p > 0.05 
(Means are the same) 
t Critical one-tail 2.353363435 
  P(T<=t) two-tail 1 
 
Accept null hypothesis because p > 0.05 
t Critical two-tail 3.182446305   
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Appendix E – Calibration Curves 
 
Ibuprofen Calibration Curve 
 
 
 
Figure 37:  IBF Calibration Curve Above pKa (λ = 195 nm) 
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Ketoprofen Calibration Curves 
 
 
Figure 38:  KTF Calibration Curve Below pKa (λ = 260 nm) 
 
 
Figure 39:  KTF Calibration Curve Above pKa (λ = 260 nm) 
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Naproxen Calibration Curves 
 
 
Figure 40:  NAP Calibration Curve Below pKa (λ = 230 nm) 
 
 
Figure 41:  NAP Calibration Curve Above pKa (λ = 230 nm) 
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Appendix F – Degradation Kinetics Raw Data 
Ibuprofen Degradation 
 
Table 10: IBF UV Degradation Above pKa 
Time (min) Corrected Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 2.0375 1.9463 1.9431 10.3008 9.8397 9.8236 0.2213 0.5496 9.9880 2.3014 0.1001 
1 1.6540 1.6528 1.6578 8.3620 8.3559 8.3812 0.0108 0.0268 8.3664 2.1242 0.1195 
2 1.1320 1.1387 1.1309 5.7230 5.7568 5.7174 0.0174 0.0433 5.7324 1.7461 0.1744 
3 1.0084 1.0032 0.9989 5.0981 5.0718 5.0501 0.0196 0.0488 5.0733 1.6240 0.1971 
4 0.9644 0.9623 0.9632 4.8756 4.8650 4.8696 0.0043 0.0108 4.8701 1.5831 0.2053 
5 0.9408 0.9389 0.9414 4.7563 4.7467 4.7594 0.0054 0.0134 4.7541 1.5590 0.2103 
10 0.3030 0.2998 0.3012 1.5319 1.5157 1.5228 0.0066 0.0164 1.5234 0.4210 0.6564 
15 0.2315 0.2307 0.2323 1.1704 1.1663 1.1744 0.0033 0.0082 1.1704 0.1573 0.8544 
20 0.2050 0.2025 0.2043 1.0364 1.0238 1.0329 0.0053 0.0132 1.0310 0.0305 0.9699 
30 0.1610 0.1608 0.1633 0.8140 0.8129 0.8256 0.0057 0.0142 0.8175 -0.2015 1.2233 
45 0.0964 0.0944 0.0933 0.4874 0.4772 0.4717 0.0065 0.0161 0.4788 -0.7365 2.0887 
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Table 11:  IBF UV/H2O2 Degradation Above pKa 
Time (min) 
Corrected Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 2.0111 1.9413 1.9478 10.1673 9.8145 9.8473 0.1592 0.3954 9.9430 2.2969 0.1006 
1 1.8485 1.8398 1.8473 9.3453 9.3013 9.3392 0.0195 0.0483 9.3286 2.2331 0.1072 
2 1.3727 1.3712 1.3785 6.9398 6.9323 6.9692 0.0159 0.0395 6.9471 1.9383 0.1439 
3 1.1751 1.1695 1.1762 5.9408 5.9125 5.9464 0.0148 0.0368 5.9333 1.7806 0.1685 
4 1.0994 1.0976 1.0979 5.5581 5.5490 5.5506 0.0040 0.0099 5.5526 1.7143 0.1801 
5 0.9652 0.9614 0.9633 4.8797 4.8605 4.8701 0.0078 0.0195 4.8701 1.5831 0.2053 
10 0.6155 0.6134 0.6187 3.1117 3.1011 3.1279 0.0110 0.0274 3.1136 1.1358 0.3212 
15 0.3171 0.3167 0.3201 1.6031 1.6011 1.6183 0.0077 0.0191 1.6075 0.4747 0.6221 
20 0.2595 0.2596 0.2587 1.3119 1.3124 1.3079 0.0020 0.0051 1.3108 0.2706 0.7629 
30 0.1687 0.1633 0.1645 0.8529 0.8256 0.8316 0.0117 0.0291 0.8367 -0.1783 1.1952 
45 0.1749 0.1733 0.1755 0.8842 0.8761 0.8873 0.0047 0.0117 0.8825 -0.1249 1.1331 
 
 
Table 12:  IBF UV/TiO2 Degradation 
Time (min) Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration [C] ln[C] [C]-1 
D1 D2 D3 D1 D2 D3 
0 1.9870 1.9419 1.9431 10.0455 9.8175 9.8236 0.1061 0.2635 9.8955 2.2921 0.1011 
5 1.0050 0.9989 1.0007 5.0809 5.0501 5.0592 0.0129 0.0321 5.0634 1.6220 0.1975 
10 0.5261 0.5165 0.5173 2.6598 2.6112 2.6153 0.0220 0.0546 2.6287 0.9665 0.3804 
15 0.3542 0.3498 0.3512 1.7907 1.7685 1.7755 0.0093 0.0231 1.7782 0.5756 0.5624 
20 0.2942 0.2916 0.3001 1.4874 1.4742 1.5172 0.0180 0.0447 1.4929 0.4007 0.6698 
30 0.2187 0.2203 0.2164 1.1057 1.1138 1.0940 0.0081 0.0201 1.1045 0.0994 0.9054 
45 0.2115 0.2107 0.2098 1.0693 1.0652 1.0607 0.0035 0.0087 1.0650 0.0630 0.9389 
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Ketoprofen Degradation 
 
Table 13:  KTF UV Degradation Below pKa 
Time (min) 
Corrected Absorbance Corrected Concentration Standard 
Deviation 
95% 
Confidence 
Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 0.6496 0.6398 0.6551 10.0870 9.9348 10.1724 0.0983 0.2441 10.0647 2.3090 0.0994 
1 0.4012 0.4055 0.4263 6.2298 6.2966 6.6196 0.1702 0.4228 6.3820 1.8535 0.1567 
2 0.3275 0.3356 0.3249 5.0854 5.2112 5.0450 0.0708 0.1758 5.1139 1.6320 0.1955 
3 0.2918 0.2834 0.2946 4.5311 4.4006 4.5745 0.0739 0.1836 4.5021 1.5045 0.2221 
4 0.2573 0.2499 0.2515 3.9953 3.8804 3.9053 0.0494 0.1226 3.9270 1.3679 0.2546 
5 0.2875 0.2796 0.2745 4.4643 4.3416 4.2624 0.0830 0.2063 4.3561 1.4716 0.2296 
10 0.0913 0.0867 0.0954 1.4177 1.3463 1.4814 0.0552 0.1371 1.4151 0.3472 0.7067 
15 0.0322 0.0356 0.0334 0.5000 0.5528 0.5186 0.0219 0.0543 0.5238 -0.6466 1.9091 
20 0.0257 0.0266 0.0233 0.3991 0.4130 0.3618 0.0216 0.0537 0.3913 -0.9383 2.5556 
45 0.0033 0.0041 0.0042 0.0512 0.0637 0.0652 0.0063 0.0155 0.0600 -2.8127 16.6552 
 
 
Table 14:  KTF UV Degradation Above pKa 
Time (min) 
Corrected Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 0.6355 0.6436 0.6364 9.7469 9.8712 9.7607 0.0556 0.1381 9.7929 2.2817 0.1021 
1 0.5437 0.5387 0.5421 8.3390 8.2623 8.3144 0.0320 0.0794 8.3052 2.1169 0.1204 
2 0.4587 0.4609 0.4546 7.0353 7.0690 6.9724 0.0400 0.0995 7.0256 1.9496 0.1423 
3 0.4279 0.4314 0.4214 6.5629 6.6166 6.4632 0.0635 0.1579 6.5475 1.8791 0.1527 
4 0.4007 0.4026 0.4175 6.1457 6.1748 6.4034 0.1152 0.2862 6.2413 1.8312 0.1602 
5 0.3535 0.3611 0.3581 5.4218 5.5383 5.4923 0.0479 0.1191 5.4842 1.7019 0.1823 
10 0.2402 0.2457 0.2504 3.6840 3.7684 3.8405 0.0639 0.1588 3.7643 1.3256 0.2657 
15 0.1559 0.1591 0.1537 2.3911 2.4402 2.3574 0.0340 0.0845 2.3962 0.8739 0.4173 
20 0.0967 0.0958 0.0981 1.4831 1.4693 1.5046 0.0145 0.0361 1.4857 0.3959 0.6731 
30 0.0704 0.0698 0.0713 1.0798 1.0706 1.0936 0.0095 0.0235 1.0813 0.0782 0.9248 
45 0.0205 0.0204 0.0204 0.3144 0.3129 0.3129 0.0007 0.0018 0.3134 -1.1603 3.1909 
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Table 15:  KTF UV/H2O2 Degradation Below pKa 
Time (min) 
Corrected Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 0.6439 0.6405 0.6465 9.9984 9.9457 10.0388 0.0381 0.0948 9.9943 2.3020 0.1001 
1 0.5205 0.5286 0.5266 8.0823 8.2081 8.1770 0.0535 0.1329 8.1558 2.0987 0.1226 
2 0.4178 0.4192 0.4098 6.4876 6.5093 6.3634 0.0643 0.1597 6.4534 1.8646 0.1550 
3 0.3581 0.3599 0.3601 5.5606 5.5885 5.5916 0.0140 0.0347 5.5802 1.7192 0.1792 
4 0.3440 0.3485 0.3435 5.3416 5.4115 5.3339 0.0349 0.0867 5.3623 1.6794 0.1865 
5 0.2840 0.2846 0.2866 4.4099 4.4193 4.4503 0.0173 0.0429 4.4265 1.4876 0.2259 
10 0.1245 0.1287 0.1257 1.9332 1.9984 1.9519 0.0274 0.0681 1.9612 0.6735 0.5099 
15 0.0678 0.0688 0.0634 1.0528 1.0683 0.9845 0.0364 0.0905 1.0352 0.0346 0.9660 
20 0.0391 0.0387 0.0392 0.6071 0.6009 0.6087 0.0034 0.0083 0.6056 -0.5016 1.6513 
30 0.0156 0.0156 0.0167 0.2422 0.2422 0.2593 0.0081 0.0200 0.2479 -1.3946 4.0334 
45 0.0164 0.0164 0.0168 0.2547 0.2547 0.2609 0.0029 0.0073 0.2567 -1.3597 3.8952 
 
 
Table 16:  KTF UV/H2O2 Degradation Above pKa 
Time (min) 
Corrected Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]-1 
D1 D2 D3 D1 D2 D3 
0 0.6370 0.6388 0.6375 9.7699 9.7975 9.7776 0.0116 0.0289 9.7817 2.2805 0.1022 
1 0.4834 0.4864 0.4794 7.4141 7.4601 7.3528 0.0440 0.1093 7.4090 2.0027 0.1350 
2 0.3851 0.3864 0.3823 5.9064 5.9264 5.8635 0.0262 0.0652 5.8988 1.7747 0.1695 
3 0.3457 0.3466 0.3421 5.3021 5.3160 5.2469 0.0298 0.0741 5.2883 1.6655 0.1891 
4 0.3139 0.3189 0.3156 4.8144 4.8911 4.8405 0.0318 0.0791 4.8487 1.5787 0.2062 
5 0.2854 0.2894 0.2814 4.3773 4.4387 4.3160 0.0501 0.1244 4.3773 1.4764 0.2285 
10 0.1426 0.1433 0.1485 2.1871 2.1979 2.2776 0.0404 0.1003 2.2209 0.7979 0.4503 
15 0.0549 0.0570 0.0586 0.8420 0.8742 0.8988 0.0232 0.0577 0.8717 -0.1373 1.1472 
20 0.0412 0.0432 0.0398 0.6319 0.6626 0.6104 0.0214 0.0532 0.6350 -0.4542 1.5749 
30 0.0176 0.0188 0.0155 0.2699 0.2883 0.2377 0.0209 0.0520 0.2653 -1.3268 3.7688 
45 0.0019 0.0019 0.0019 0.0287 0.0291 0.0291 0.0002 0.0005 0.0290 -3.5409 34.4974 
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Table 17:  KTF UV/TiO2 Degradation Below pKa 
Time (min) Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]-1 
D1 D2 D3 D1 D2 D3 
0 0.6358 0.6402 0.6398 9.8727 9.9410 9.9348 0.0308 0.0766 9.9161 2.2942 0.1008 
5 0.3064 0.3023 0.3105 4.7578 4.6941 4.8214 0.0520 0.1291 4.7578 1.5598 0.2102 
10 0.1309 0.1314 0.1365 2.0326 2.0404 2.1196 0.0393 0.0976 2.0642 0.7247 0.4845 
15 0.0876 0.0864 0.0833 1.3602 1.3416 1.2935 0.0281 0.0699 1.3318 0.2865 0.7509 
20 0.0645 0.0633 0.0679 1.0016 0.9829 1.0543 0.0303 0.0751 1.0129 0.0129 0.9872 
30 0.0553 0.0542 0.0572 0.8587 0.8416 0.8882 0.0192 0.0478 0.8628 -0.1475 1.1590 
45 0.0164 0.0157 0.0172 0.2547 0.2438 0.2671 0.0095 0.0236 0.2552 -1.3658 3.9189 
 
 
Table 18:  KTF UV/TiO2 Degradation Above pKa 
Time (min) 
Corrected Absorbance Corrected Concetration 
Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 0.6384 0.6345 0.6367 9.7914 9.7316 9.7653 0.0245 0.0608 9.7628 2.2786 0.1024 
5 0.3509 0.3537 0.3566 5.3819 5.4248 5.4693 0.0357 0.0887 5.4254 1.6911 0.1843 
10 0.2272 0.2294 0.2234 3.4847 3.5184 3.4264 0.0380 0.0944 3.4765 1.2460 0.2876 
15 0.1630 0.1684 0.1694 2.5000 2.5828 2.5982 0.0431 0.1071 2.5603 0.9401 0.3906 
20 0.1369 0.1313 0.1377 2.0997 2.0138 2.1120 0.0437 0.1085 2.0752 0.7300 0.4819 
30 0.1021 0.1031 0.1022 1.5660 1.5813 1.5675 0.0069 0.0171 1.5716 0.4521 0.6363 
45 0.0921 0.0911 0.0898 1.4126 1.3972 1.3773 0.0144 0.0359 1.3957 0.3334 0.7165 
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Naproxen Degradation 
 
Table 19:  NAP UV Degradation Below pKa 
Time (min) 
Corrected Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 2.5726 2.5928 2.5836 9.4028 9.4766 9.4430 0.0302 0.0750 9.4408 2.2450 0.1059 
1 1.5710 1.5705 1.5699 5.7420 5.7401 5.7379 0.0016 0.0041 5.7400 1.7475 0.1742 
2 1.0494 1.0567 1.0433 3.8355 3.8622 3.8132 0.0200 0.0497 3.8370 1.3447 0.2606 
3 1.0016 0.9998 1.0047 3.6608 3.6542 3.6721 0.0074 0.0184 3.6624 1.2981 0.2730 
4 0.8645 0.8567 0.8582 3.1597 3.1312 3.1367 0.0124 0.0307 3.1425 1.1450 0.3182 
5 0.7691 0.7617 0.7703 2.8110 2.7840 2.8154 0.0139 0.0345 2.8035 1.0309 0.3567 
10 0.3172 0.3098 0.3107 1.1594 1.1323 1.1356 0.0120 0.0299 1.1424 0.1332 0.8753 
15 0.1010 0.0999 0.1003 0.3692 0.3651 0.3666 0.0017 0.0041 0.3670 -1.0025 2.7251 
20 0.0839 0.0811 0.0867 0.3067 0.2964 0.3169 0.0084 0.0208 0.3067 -1.1820 3.2610 
30 0.0561 0.0577 0.0532 0.2050 0.2109 0.1944 0.0068 0.0169 0.2035 -1.5923 4.9150 
45 0.0249 0.0233 0.0213 0.0910 0.0852 0.0779 0.0054 0.0134 0.0847 -2.4690 11.8101 
 
 
Table 20:  NAP UV Degradation Above pKa 
Time (min) 
Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 2.7170 2.7254 2.7365 9.2889 9.3176 9.3556 0.0273 0.0678 9.3207 2.2322 0.1073 
1 2.5107 2.5206 2.4917 8.5836 8.6174 8.5186 0.0410 0.1018 8.5732 2.1486 0.1166 
2 2.0466 2.0266 2.0794 6.9969 6.9285 7.1091 0.0744 0.1849 7.0115 1.9476 0.1426 
3 1.7580 1.7426 1.7609 6.0103 5.9576 6.0202 0.0275 0.0682 5.9960 1.7911 0.1668 
4 1.7143 1.7062 1.7208 5.8609 5.8332 5.8831 0.0204 0.0507 5.8590 1.7680 0.1707 
5 1.3203 1.3128 1.3256 4.5138 4.4882 4.5320 0.0180 0.0446 4.5113 1.5066 0.2217 
10 0.4163 0.4201 0.4154 1.4232 1.4362 1.4202 0.0070 0.0173 1.4266 0.3553 0.7010 
15 0.2330 0.2298 0.2314 0.7966 0.7856 0.7911 0.0045 0.0111 0.7911 -0.2343 1.2640 
20 0.1407 0.1385 0.1423 0.4810 0.4735 0.4865 0.0053 0.0132 0.4803 -0.7333 2.0819 
30 0.0354 0.0336 0.0384 0.1210 0.1149 0.1313 0.0068 0.0168 0.1224 -2.1005 8.1704 
45 0.0215 0.0212 0.0216 0.0735 0.0725 0.0738 0.0006 0.0014 0.0733 -2.6135 13.6470 
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Table 21:  NAP UV/H2O2 Degradation Below pKa 
Time (min) 
Corrected Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence 
Mean 
Concentration 
ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 2.5726 2.5802 2.5758 9.4028 9.4306 9.4145 0.0114 0.0283 9.4159 2.2424 0.1062 
1 1.9434 1.9398 1.9456 7.1031 7.0899 7.1111 0.0087 0.0217 7.1014 1.9603 0.1408 
2 1.4999 1.4987 1.5043 5.4821 5.4777 5.4982 0.0088 0.0219 5.4860 1.7022 0.1823 
3 1.2498 1.2508 1.2456 4.5680 4.5716 4.5526 0.0082 0.0205 4.5641 1.5182 0.2191 
4 1.1610 1.1645 1.1578 4.2434 4.2562 4.2317 0.0100 0.0248 4.2438 1.4455 0.2356 
5 0.8508 0.8467 0.8534 3.1096 3.0947 3.1192 0.0101 0.0250 3.1078 1.1339 0.3218 
10 0.3035 0.3021 0.3056 1.1093 1.1042 1.1170 0.0053 0.0131 1.1101 0.1045 0.9008 
15 0.1696 0.1708 0.1732 0.6199 0.6243 0.6330 0.0055 0.0136 0.6257 -0.4688 1.5981 
20 0.0618 0.0597 0.0632 0.2259 0.2182 0.2310 0.0053 0.0131 0.2250 -1.4915 4.4440 
30 0.0287 0.0256 0.0243 0.1049 0.0936 0.0888 0.0067 0.0168 0.0958 -2.3459 10.4427 
45 0.0295 0.0290 0.0291 0.1078 0.1060 0.1064 0.0008 0.0020 0.1067 -2.2375 9.3699 
 
 
Table 22:  NAP UV/H2O2 Degradation Above pKa 
Time (min) 
Corrected Absorbance Corrected Concetration 
Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 2.7029 2.7123 2.7054 9.2407 9.2728 9.2492 0.0136 0.0338 9.2542 2.2251 0.1081 
1 2.1440 2.1432 2.1023 7.3299 7.3272 7.1874 0.0666 0.1654 7.2815 1.9853 0.1373 
2 1.5525 1.5523 1.5421 5.3077 5.3070 5.2721 0.0166 0.0412 5.2956 1.6669 0.1888 
3 1.3804 1.3778 1.3789 4.7193 4.7104 4.7142 0.0036 0.0091 4.7146 1.5507 0.2121 
4 1.1869 1.1859 1.1846 4.0578 4.0544 4.0499 0.0032 0.0080 4.0540 1.3997 0.2467 
5 0.9739 0.9678 0.9734 3.3296 3.3087 3.3279 0.0095 0.0235 3.3221 1.2006 0.3010 
10 0.3915 0.3878 0.3923 1.3385 1.3258 1.3412 0.0067 0.0166 1.3352 0.2890 0.7490 
15 0.2264 0.2254 0.2266 0.7740 0.7706 0.7747 0.0018 0.0045 0.7731 -0.2573 1.2935 
20 0.0943 0.0912 0.0898 0.3224 0.3118 0.3070 0.0064 0.0160 0.3137 -1.1592 3.1874 
30 0.0656 0.0634 0.0623 0.2243 0.2168 0.2130 0.0047 0.0117 0.2180 -1.5232 4.5870 
45 0.0479 0.0473 0.0480 0.1638 0.1617 0.1641 0.0011 0.0026 0.1632 -1.8128 6.1278 
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Table 23:  NAP UV/TiO2 Degradation Below pKa 
Time (min) Absorbance 
Corrected 
Concentration Standard Deviation 95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 2.5807 2.6107 2.5918 9.4324 9.5420 9.4730 0.0453 0.1124 9.4825 2.2494 0.1055 
5 1.1541 1.1432 1.1503 4.2182 4.1784 4.2043 0.0165 0.0410 4.2003 1.4352 0.2381 
10 0.6084 0.6023 0.6010 2.2237 2.2014 2.1966 0.0118 0.0293 2.2072 0.7917 0.4531 
15 0.2915 0.2922 0.2904 1.0654 1.0680 1.0614 0.0027 0.0067 1.0649 0.0629 0.9390 
20 0.1168 0.1154 0.1142 0.4269 0.4218 0.4174 0.0039 0.0096 0.4220 -0.8627 2.3695 
30 0.1040 0.1021 0.1038 0.3801 0.3732 0.3794 0.0031 0.0077 0.3776 -0.9740 2.6486 
45 0.0857 0.0843 0.0813 0.3132 0.3081 0.2971 0.0067 0.0167 0.3062 -1.1836 3.2662 
 
 
Table 24:  NAP UV/TiO2 Degradation Above pKa 
Time (min) 
Corrected Absorbance 
Corrected 
Concentration Standard 
Deviation 
95% Confidence Mean Concentration ln[C] [C]
-1
 
D1 D2 D3 D1 D2 D3 
0 2.6807 2.6901 2.6837 9.1648 9.1969 9.1750 0.0134 0.0333 9.1789 2.2169 0.1089 
5 1.1038 1.0980 1.1017 3.7737 3.7538 3.7665 0.0082 0.0204 3.7647 1.3257 0.2656 
10 0.4994 0.4972 0.5001 1.7074 1.6998 1.7097 0.0042 0.0105 1.7056 0.5339 0.5863 
15 0.2848 0.2798 0.2812 0.9737 0.9566 0.9614 0.0072 0.0179 0.9639 -0.0368 1.0375 
20 0.1432 0.1422 0.1449 0.4896 0.4862 0.4954 0.0038 0.0095 0.4904 -0.7126 2.0393 
30 0.1358 0.1369 0.1319 0.4643 0.4680 0.4509 0.0073 0.0182 0.4611 -0.7742 2.1688 
45 0.0858 0.0847 0.0819 0.2933 0.2896 0.2800 0.0056 0.0139 0.2876 -1.2461 3.4766 
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Appendix G – Degradation Curves 
Ibuprofen 
 
 
Figure 42:  IBF UV Degradation Curve Above pKa (λ = 195 nm) 
 
 
 
Figure 43:  IBF UV/H2O2 Degradation Curve Above pKa (λ = 195 nm) 
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Figure 44:  IBF UV/TiO2 Degradation Curve Above pKa (λ = 195 nm) 
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Ketoprofen 
 
 
Figure 45:  KTF UV Degradation Curve Below pKa (λ = 260 nm) 
 
 
 
Figure 46:  KTF UV Degradation Curve Above pKa (λ = 260 nm) 
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Figure 47:  KTF UV/H2O2 Degradation Curve Below pKa (λ = 260 nm) 
 
 
 
Figure 48:  KTF UV/H2O2 Degradation Curve Above pKa (λ = 260 nm) 
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Figure 49:  KTF UV/TiO2 Degradation Curve Below pKa (λ = 260 nm) 
 
 
 
Figure 50:  KTF UV/TiO2 Degradation Curve Above pKa (λ = 260 nm) 
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Naproxen 
 
 
 
Figure 51:  NAP UV Degradation Curve Below pKa (λ = 230 nm) 
 
 
 
Figure 52:  NAP UV Degradation Curve Above pKa (λ = 230 nm) 
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Figure 53:  NAP UV/H2O2 Degradation Curve Below pKa (λ = 230 nm) 
 
 
 
Figure 54:  NAP UV/H2O2 Degradation Curve Above pKa (λ = 230 nm) 
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Figure 55:  NAP UV/TiO2 Degradation Curve Below pKa (λ = 230 nm) 
 
 
 
Figure 56:  NAP UV/TiO2 Degradation Curve Above pKa (λ = 230 nm) 
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Appendix H – Kinetics Curves 
Ibuprofen 
 
 
Figure 57:  IBF 1st Order UV Kinetics Above pKa (λ = 195 nm) 
 
 
 
Figure 58:  IBF 2nd Order UV Kinetics Above pKa (λ = 195 nm) 
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Figure 59:  IBF 1st Order UV/H2O2 Kinetics Above pKa (λ = 195 nm) 
 
 
 
Figure 60:  IBF 2nd Order UV/H2O2 Kinetics Above pKa (λ = 195 nm) 
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Figure 61:  IBF 1st Order UV/TiO2 Kinetics Above pKa (λ = 195 nm) 
 
 
 
Figure 62:  IBF 2nd Order UV/TiO2 Kinetics Above pKa (λ = 195 nm) 
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Ketoprofen 
 
 
Figure 63:  KTF 1st Order UV Kinetics Below pKa (λ = 260 nm) 
 
 
 
Figure 64:  KTF 2nd Order UV Kinetics Below pKa (λ = 260 nm) 
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Figure 65:  KTF 1st Order UV Kinetics Above pKa (λ = 260 nm) 
 
 
 
Figure 66:  KTF 2nd Order UV Kinetics Above pKa (λ = 260 nm) 
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Figure 67:  KTF 1st Order UV/H2O2 Kinetics Below pKa (λ = 260 nm) 
 
 
 
Figure 68:  KTF 2nd Order UV/H2O2 Kinetics Below pKa (λ = 260 nm) 
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Figure 69:  KTF 1st Order UV/H2O2 Kinetics Above pKa (λ = 260 nm) 
 
 
 
Figure 70:  KTF 2nd Order UV/H2O2 Kinetics Above pKa (λ = 260 nm) 
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Figure 71:  KTF 1st Order UV/TiO2 Kinetics Below pKa (λ = 260 nm) 
 
 
 
Figure 72:  KTF 2nd Order UV/TiO2 Kinetics Below pKa (λ = 260 nm) 
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Figure 73:  KTF 1st Order UV/TiO2 Kinetics Above pKa (λ = 260 nm) 
 
 
 
Figure 74:  KTF 2nd Order UV/TiO2 Kinetics Above pKa (λ = 260 nm) 
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Naproxen 
 
 
 
Figure 75:  NAP 1st Order UV Kinetics Below pKa (λ = 230 nm) 
 
 
 
Figure 76:  NAP 2nd Order UV Kinetics Below pKa (λ = 230 nm) 
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Figure 77:  NAP 1st Order UV Kinetics Above pKa (λ = 230 nm) 
 
 
 
Figure 78:  NAP 2nd Order UV Kinetics:  Above pKa (λ = 230 nm) 
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Figure 79:  NAP 1st Order UV/H2O2 Kinetics Below pKa (λ = 230 nm) 
 
 
 
Figure 80:  NAP 2nd Order UV/H2O2 Kinetics Below pKa (λ = 230 nm) 
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Figure 81:  NAP 1st Order UV/H2O2 Kinetics Above pKa (λ = 230 nm) 
 
 
 
Figure 82:  NAP 2nd Order UV/H2O2 Kinetics Above pKa (λ = 230 nm) 
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Figure 83:  NAP 1st Order UV/TiO2 Kinetics Below pKa (λ = 230 nm) 
 
 
 
Figure 84:  NAP 2nd Order UV/TiO2 Kinetics Below pKa (λ = 230 nm) 
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Figure 85:  NAP 1st Order UV/TiO2 Kinetics Above pKa (λ = 230 nm) 
 
 
 
Figure 86:  NAP 2nd Order UV/TiO2 Kinetics Above pKa (λ = 230 nm) 
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Appendix I – Gas Chromatography and Evaporator Settings 
 
RapidVap Labconco Evaporator Settings: 
 
 Preheat Temperature:  80°C 
 RPM Value:  90% 
 Evaporation Time:  30 minutes 
 
Instrumentation:  Agilent 6890N Network GC System 
Column: J & W 123 – 1334 (260°C Max) DB-624 Capillary 30 m x 320 µm x 1.8 µm 
Mode:  Constant Pressure 
Flow:  1.3 mL min
-1 
Average Velocity:  27 cm min
-1 
 
 
 
Table 25:  Gas Chromatography Parameters 
Front Inlet Temperature 
250 °C, Splitless Mode 
Front Inlet Pressure 4.0 psi 
Purge Time 
0.4 min 
Purge Flow 
106 mL min
-1
 
Total Flow 110 mL min
-1
 
Oven Ramp 
Held at 100 °C for 2 min, then heated to 180 °C at a heating rate of 4 
°C/min, then heated to 230 °C at 10 °C/min and held for 20 min, then 
ramped at 20 °C to 260 °C for 7 min. 
 
Carrier Gas 
Helium 
FID Temperaure 250 °C 
H2 Flow 40 mL min
-1 
Air Flow 450 mL min
-1 
Make – Up Flow Nitrogen @ 3.0 mL min-1 
Lit Offset 2.0 
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Appendix J – Gas Chromatography Calibration Curve Raw Data 
 
Table 26:  IBF GC Calibration Curve Data 
Concentration 
(ppm) 
Area 
Mean Area 
Standard 
Deviation 
95% 
Confidence D1 D2 D3 
50 18000.0 19500.0 17700.0 18400.0000 787.4008 1956.0120 
10 4584.0 4263.0 3603.0 4150.0000 408.3846 1014.4836 
1 326.4 313.2 265.7 301.7667 26.0661 64.7518 
0.5 165.1 167.5 155.1 162.5667 5.3699 13.3395 
0.1 44.9 38.7 40.1 41.2167 2.6320 6.5382 
 
 
Table 27:  KTF GC Calibration Curve Data 
Concentration 
(ppm) 
Area 
Mean Area 
Standard 
Deviation 
95% 
Confidence D1 D2 D3 
50 8928.4 10585.2 10340.0 9951.2000 730.1236 1813.7275 
10 1276.4 1051.1 937.4 1088.3000 140.8738 349.9499 
1 169.0 166.5 171.2 168.8967 1.9199 4.7693 
0.5 58.6 75.8 69.8 68.0333 7.1461 17.7520 
 
 
Table 28:  NAP GC Calibration Curve Data 
Concentration (ppm) 
Area 
Mean Area 
Standard 
Deviation 
95% 
Confidence D1 D2 D3 
10 2573.3 2316.1 2574.7 2488.0433 121.5836 302.0305 
1 246.2 168.6 194.5 203.1133 32.2763 80.1787 
0.5 83.7 82.3 80.3 82.0667 1.3738 3.4126 
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Appendix K – Gas Chromatograms 
 












































































